The thioredoxin (Trx) system comprises Trx, truncated Trx (Trx-80), Trx reductase, and NADPH, besides a natural Trx inhibitor, the thioredoxin-interacting protein (TXNIP). This system is essential for maintaining the balance of the cellular redox status, and it is involved in the regulation of redox signaling. It is also pivotal for growth promotion, neuroprotection, inflammatory modulation, antiapoptosis, immune function, and atherosclerosis. As an ubiquitous and multifunctional protein, Trx is expressed in all forms of life, executing its function through its antioxidative, protein-reducing, and signal-transducing activities. In this review, the biological properties of the Trx system are highlighted, and its implications in several human diseases are discussed, including cardiovascular diseases, heart failure, stroke, inflammation, metabolic syndrome, neurodegenerative diseases, arthritis, and cancer. The last chapter addresses the emerging therapeutic approaches targeting the Trx system in human diseases. Antioxid. Redox Signal. 19, 1266–1303.
AbateC, PatelL, RauscherFJ3rd, CurranT. Redox regulation of fos and jun DNA-binding activity in vitro. Science, 249:1157–1161. 1990.
2.
AdluriRS, ThirunavukkarasuM, ZhanL, AkitaY, SamuelSM, OtaniH, HoYS, MaulikG, MaulikN. Thioredoxin 1 enhances neovascularization and reduces ventricular remodeling during chronic myocardial infarction: a study using thioredoxin 1 transgenic mice. J Mol Cell Cardiol, 50:239–247. 2011.
3.
AdoriniL, GiarratanaN, PennaG. Pharmacological induction of tolerogenic dendritic cells and regulatory T cells. Semin Immunol, 16:127–134. 2004.
4.
AgoT, LiuT, ZhaiP, ChenW, LiH, MolkentinJD, VatnerSF, SadoshimaJ. A redox-dependent pathway for regulating class II HDACs and cardiac hypertrophy. Cell, 133:978–993. 2008.
5.
AgoT, SadoshimaJ. Thioredoxin1 as a negative regulator of cardiac hypertrophy. Antioxid Redox Signal, 9:679–687. 2007.
6.
Aguado-LleraD, Martinez-GomezAI, PrietoJ, MarenchinoM, TraversoJA, GomezJ, ChuecaA, NeiraJL. The conformational stability and biophysical properties of the eukaryotic thioredoxins of Pisum sativum are not family-conserved. PLoS One, 6:e17068. 2011.
7.
AhsanMK, LekliI, RayD, YodoiJ, DasDK. Redox regulation of cell survival by the thioredoxin superfamily: an implication of redox gene therapy in the heart. Antioxid Redox Signal, 11:2741–2758. 2009.
8.
AhsanMK, MasutaniH, YamaguchiY, KimYC, NosakaK, MatsuokaM, NishinakaY, MaedaM, YodoiJ. Loss of interleukin-2-dependency in HTLV-I-infected T cells on gene silencing of thioredoxin-binding protein-2. Oncogene, 25:2181–2191. 2006.
9.
AkterinS, CowburnRF, Miranda-VizueteA, JimenezA, BogdanovicN, WinbladB, Cedazo-MinguezA. Involvement of glutaredoxin-1 and thioredoxin-1 in beta-amyloid toxicity and Alzheimer's disease. Cell Death Differ, 13:1454–1465. 2006.
10.
Al-GayyarMM, AbdelsaidMA, MatragoonS, PillaiBA, El-RemessyAB. Thioredoxin interacting protein is a novel mediator of retinal inflammation and neurotoxicity. Br J Pharmacol, 164:170–180. 2011.
11.
AlessioHM. Exercise-induced oxidative stress. Med Sci Sports Exerc, 25:218–224. 1993.
12.
AltschmiedJ, HaendelerJ. Thioredoxin-1 and endothelial cell aging: role in cardiovascular diseases. Antioxid Redox Signal, 11:1733–1740. 2009.
13.
AnandPK, MalireddiRK, KannegantiTD. Role of the nlrp3 inflammasome in microbial infection. Front Microbiol, 2:12. 2011.
14.
AnjuereF, MartinP, FerreroI, FragaML, del HoyoGM, WrightN, ArdavinC. Definition of dendritic cell subpopulations present in the spleen, Peyer's patches, lymph nodes, and skin of the mouse. Blood, 93:590–598. 1999.
15.
AraiRJ, MasutaniH, YodoiJ, DebbasV, LaurindoFR, SternA, MonteiroHP. Nitric oxide induces thioredoxin-1 nuclear translocation: possible association with the p21Ras survival pathway. Biochem Biophys Res Commun, 348:1254–1260. 2006.
16.
ArnerES. Focus on mammalian thioredoxin reductases—important selenoproteins with versatile functions. Biochim Biophys Acta, 1790:495–526. 2009.
17.
ArnerES, HolmgrenA. Physiological functions of thioredoxin and thioredoxin reductase. Eur J Biochem, 267:6102–6109. 2000.
18.
ArnerES, HolmgrenA. The thioredoxin system in cancer. Semin Cancer Biol, 16:420–426. 2006.
19.
ArnerES, NakamuraH, SasadaT, YodoiJ, HolmgrenA, SpyrouG. Analysis of the inhibition of mammalian thioredoxin, thioredoxin reductase, and glutaredoxin by cis-diamminedichloroplatinum (II) and its major metabolite, the glutathione-platinum complex. Free Radic Biol Med, 31:1170–1178. 2001.
20.
ArtlettCM, Sassi-GahaS, RiegerJL, BoesteanuAC, Feghali-BostwickCA, KatsikisPD. The inflammasome activating caspase 1 mediates fibrosis and myofibroblast differentiation in systemic sclerosis. Arthritis Rheum, 63:3563–3574. 2011.
21.
AtalayM, SenCK. Physical exercise and antioxidant defenses in the heart. Ann N Y Acad Sci, 874:169–177. 1999.
22.
AverySV. Molecular targets of oxidative stress. Biochem J, 434:201–210. 2011.
23.
BachnoffN, TrusM, AtlasD. Alleviation of oxidative stress by potent and selective thioredoxin-mimetic peptides. Free Radic Biol Med, 50:1355–1367. 2011.
24.
BaiJ, NakamuraH, HattoriI, TanitoM, YodoiJ. Thioredoxin suppresses 1-methyl-4-phenylpyridinium-induced neurotoxicity in rat PC12 cells. Neurosci Lett, 321:81–84. 2002.
25.
BaiJ, NakamuraH, KwonYW, TanitoM, UedaS, TanakaT, HattoriI, BanS, MomoiT, KitaoY, OgawaS, YodoiJ. Does thioredoxin-1 prevent mitochondria- and endoplasmic reticulum-mediated neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine?Antioxid Redox Signal, 9:603–608. 2007.
26.
BanHS, UtoY, NakamuraH. Hypoxia-inducible factor inhibitors: a survey of recent patented compounds (2004–2010)Expert Opin Ther Pat, 21:131–146. 2011.
27.
BeckerK, GromerS, SchirmerRH, MullerS. Thioredoxin reductase as a pathophysiological factor and drug target. Eur J Biochem, 267:6118–6125. 2000.
BellKF, HardinghamGE. CNS peroxiredoxins and their regulation in health and disease. Antioxid Redox Signal, 14:1467–1477. 2011.
30.
BenharM, ForresterMT, HessDT, StamlerJS. Regulated protein denitrosylation by cytosolic and mitochondrial thioredoxins. Science, 320:1050–1054. 2008.
31.
BerggrenM, GallegosA, GasdaskaJR, GasdaskaPY, WarnekeJ, PowisG. Thioredoxin and thioredoxin reductase gene expression in human tumors and cell lines, and the effects of serum stimulation and hypoxia. Anticancer Res, 16:3459–3466. 1996.
32.
BerndtC, LilligCH, HolmgrenA. Thioredoxins and glutaredoxins as facilitators of protein folding. Biochim Biophys Acta, 1783:641–650. 2008.
33.
BertiniR, HowardOM, DongHF, OppenheimJJ, BizzarriC, SergiR, CaselliG, PaglieiS, RominesB, WilshireJA, MengozziM, NakamuraH, YodoiJ, PekkariK, GurunathR, HolmgrenA, HerzenbergLA, HerzenbergLA, GhezziP. Thioredoxin, a redox enzyme released in infection and inflammation, is a unique chemoattractant for neutrophils, monocytes, and T cells. J Exp Med, 189:1783–1789. 1999.
34.
BigelowDJ, SquierTC. Thioredoxin-dependent redox regulation of cellular signaling and stress response through reversible oxidation of methionines. Mol Biosyst, 7:2101–2109. 2011.
35.
BillietL, FurmanC, Cuaz-PerolinC, PaumelleR, RaymondjeanM, SimmetT, RouisM. Thioredoxin-1 and its natural inhibitor, vitamin D3 up-regulated protein 1, are differentially regulated by PPARalpha in human macrophages. J Mol Biol, 384:564–576. 2008.
36.
BillietL, FurmanC, LarigauderieG, CopinC, BrandK, FruchartJC, RouisM. Extracellular human thioredoxin-1 inhibits lipopolysaccharide-induced interleukin-1beta expression in human monocyte-derived macrophages. J Biol Chem, 280:40310–40318. 2005.
37.
BirrellMA, EltomS. The role of the NLRP3 Inflammasome in the pathogenesis of airway disease. Pharmacol Ther, 130:364–370. 2011.
38.
BjornstedtM, HambergM, KumarS, XueJ, HolmgrenA. Human thioredoxin reductase directly reduces lipid hydroperoxides by NADPH and selenocystine strongly stimulates the reaction via catalytically generated selenols. J Biol Chem, 270:11761–11764. 1995.
39.
BloomfieldKL, OsborneSA, KennedyDD, ClarkeFM, TonissenKF. Thioredoxin-mediated redox control of the transcription factor Sp1 and regulation of the thioredoxin gene promoter. Gene, 319:107–116. 2003.
40.
BodnarJS, ChatterjeeA, CastellaniLW, RossDA, OhmenJ, CavalcoliJ, WuC, DainsKM, CataneseJ, ChuM, ShethSS, CharugundlaK, DemantP, WestDB, de JongP, LusisAJ. Positional cloning of the combined hyperlipidemia gene Hyplip1. Nat Genet, 30:110–116. 2002.
41.
BonifatiV, RizzuP, van BarenMJ, SchaapO, BreedveldGJ, KriegerE, DekkerMC, SquitieriF, IbanezP, JoosseM, van DongenJW, VanacoreN, van SwietenJC, BriceA, MecoG, van DuijnCM, OostraBA, HeutinkP. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science, 299:256–259. 2003.
42.
BrazilDP, YangZZ, HemmingsBA. Advances in protein kinase B signalling: AKTion on multiple fronts. Trends Biochem Sci, 29:233–242. 2004.
43.
BrookmeyerR, EvansDA, HebertL, LangaKM, HeeringaSG, PlassmanBL, KukullWA. National estimates of the prevalence of Alzheimer's disease in the United States. Alzheimers Dement, 7:61–73.
44.
BurragePS, MixKS, BrinckerhoffCE. Matrix metalloproteinases: role in arthritis. Front Biosci, 11:529–543. 2006.
45.
ButlerLM, ZhouX, XuWS, ScherHI, RifkindRA, MarksPA, RichonVM. The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin. Proc Natl Acad Sci U S A, 99:11700–11705. 2002.
46.
CaiW, ZhangB, DuanD, WuJ, FangJ. Curcumin targeting the thioredoxin system elevates oxidative stress in HeLa cells. Toxicol Appl Pharmacol, 262:341–348. 2012.
CallisterME, Burke-GaffneyA, QuinlanGJ, NicholsonAG, FlorioR, NakamuraH, YodoiJ, EvansTW. Extracellular thioredoxin levels are increased in patients with acute lung injury. Thorax, 61:521–527. 2006.
49.
CarlsonBA, YooMH, TobeR, MuellerC, Naranjo-SuarezS, HoffmannVJ, GladyshevVN, HatfieldDL. Thioredoxin reductase 1 protects against chemically induced hepatocarcinogenesis via control of cellular redox homeostasis. Carcinogenesis, 33:1806–1813. 2012.
50.
CasagrandeS, BonettoV, FratelliM, GianazzaE, EberiniI, MassignanT, SalmonaM, ChangG, HolmgrenA, GhezziP. Glutathionylation of human thioredoxin: a possible crosstalk between the glutathione and thioredoxin systems. Proc Natl Acad Sci U S A, 99:9745–9749. 2002.
51.
CasiniA, MessoriL. Molecular mechanisms and proposed targets for selected anticancer gold compounds. Curr Top Med Chem, 11:2647–2660. 2011.
52.
CassidyPB, EdesK, NelsonCC, ParsawarK, FitzpatrickFA, MoosPJ. Thioredoxin reductase is required for the inactivation of tumor suppressor p53 and for apoptosis induced by endogenous electrophiles. Carcinogenesis, 27:2538–2549. 2006.
53.
CeconiC, BorasoA, CargnoniA, FerrariR. Oxidative stress in cardiovascular disease: myth or fact?Arch Biochem Biophys, 420:217–221. 2003.
54.
CenasN, PrastS, NivinskasH, SarlauskasJ, ArnerES. Interactions of nitroaromatic compounds with the mammalian selenoprotein thioredoxin reductase and the relation to induction of apoptosis in human cancer cells. J Biol Chem, 281:5593–5603. 2006.
ChakrabortiPK, GarabedianMJ, YamamotoKR, SimonsSSJr. Role of cysteines 640, 656, and 661 in steroid binding to rat glucocorticoid receptors. J Biol Chem, 267:11366–11373. 1992.
59.
ChangJC, KouSJ, LinWT, LiuCS. Regulatory role of mitochondria in oxidative stress and atherosclerosis. World J Cardiol, 2:150–159. 2010.
60.
CharlesRL, BurgoyneJR, EatonP. Mechanisms of redox signaling in cardiovascular disease. Studies on Cardiovascular Disorders. New York: Springer, 43–60.
61.
ChenB, GuanD, CuiZJ, WangX, ShenX. Thioredoxin 1 downregulates MCP-1 secretion and expression in human endothelial cells by suppressing nuclear translocation of activator protein 1 and redox factor-1. Am J Physiol Cell Physiol, 298:C1170–C1179. 2010.
62.
ChenJ, GanY, JiX, HuX, LuoY, ZhangL, LiP, LiuX, YanF, VoslerP, GaoY, StetlerRA. Transgenic overexpression of peroxiredoxin-2 attenuates ischemic neuronal injury via suppression of a redox-sensitive pro-death signaling pathway. Antioxid Redox Signal, 17:719–732. 2012.
63.
ChenKS, DeLucaHF. Isolation and characterization of a novel cDNA from HL-60 cells treated with 1,25-dihydroxyvitamin D-3. Biochim Biophys Acta, 1219:26–32. 1994.
64.
ChenMH, LeeMY, ChuangJJ, LiYZ, NingST, ChenJC, LiuYW. Curcumin inhibits HCV replication by induction of heme oxygenase-1 and suppression of AKT. Int J Mol Med, 30:1021–1028. 2012.
65.
ChenVT, HuangCL, LeeYC, LiaoWC, HuangNK. The roles of the thioredoxin system and peroxiredoxins in 1-methyl-4-phenyl-pyridinium ion-induced cytotoxicity in rat pheochromocytoma cells. Toxicol In Vitro, 24:1577–1583. 2010.
66.
ChenX, TangW, LiuS, YuL, ChenZ. Thioredoxin-1 phosphorylated at T100 is needed for its anti-apoptotic activity in HepG2 cancer cells. Life Sci, 87:254–260. 2010.
67.
ChenY, CaiJ, MurphyTJ, JonesDP. Overexpressed human mitochondrial thioredoxin confers resistance to oxidant-induced apoptosis in human osteosarcoma cells. J Biol Chem, 277:33242–33248. 2002.
68.
ChoiJ, SullardsMC, OlzmannJA, ReesHD, WeintraubST, BostwickDE, GearingM, LeveyAI, ChinLS, LiL. Oxidative damage of DJ-1 is linked to sporadic Parkinson and Alzheimer diseases. J Biol Chem, 281:10816–10824. 2006.
69.
ChoiTG, LeeJ, HaJ, KimSS. Apoptosis signal-regulating kinase 1 is an intracellular inducer of p38 MAPK-mediated myogenic signalling in cardiac myoblasts. Biochim Biophys Acta, 1813:1412–1421. 2011.
70.
ChuangCY, ChangCH, HuangYL. Thioredoxin mediates remodeling factors of human bronchial epithelial cells upon interaction with house dust mite-stimulated eosinophils. Inhal Toxicol, 21:153–167. 2009.
71.
ChungJW, JeonJH, YoonSR, ChoiI. Vitamin D3 upregulated protein 1 (VDUP1) is a regulator for redox signaling and stress-mediated diseases. J Dermatol, 33:662–669. 2006.
72.
ChutkowWA, BirkenfeldAL, BrownJD, LeeHY, FrederickDW, YoshiokaJ, PatwariP, KursaweR, CushmanSW, PlutzkyJ, ShulmanGI, SamuelVT, LeeRT. Deletion of the alpha-arrestin protein Txnip in mice promotes adiposity and adipogenesis while preserving insulin sensitivity. Diabetes, 59:1424–1434. 2010.
73.
ChutkowWA, LeeRT. Thioredoxin regulates adipogenesis through thioredoxin-interacting protein (Txnip) protein stability. J Biol Chem, 286:29139–29145. 2011.
74.
ChutkowWA, PatwariP, YoshiokaJ, LeeRT. Thioredoxin-interacting protein (Txnip) is a critical regulator of hepatic glucose production. J Biol Chem, 283:2397–2406. 2008.
75.
CohenG, FarooquiR, KeslerN. Parkinson disease: a new link between monoamine oxidase and mitochondrial electron flow. Proc Natl Acad Sci U S A, 94:4890–4894. 1997.
76.
ConnollyPH, CaiozzoVJ, ZaldivarF, NemetD, LarsonJ, HungSP, HeckJD, HatfieldGW, CooperDM. Effects of exercise on gene expression in human peripheral blood mononuclear cells. J Appl Physiol, 97:1461–1469. 2004.
77.
CookC, StetlerC, PetrucelliL. Disruption of protein quality control in Parkinson's disease. Cold Spring Harb Perspect Med, 2:a009423. 2012.
78.
CorbettJA. Thioredoxin-interacting protein is killing my beta-cells!Diabetes, 57:797–798. 2008.
Dal PiazF, BracaA, BelisarioMA, De TommasiN. Thioredoxin system modulation by plant and fungal secondary metabolites. Curr Med Chem, 17:479–494. 2010.
81.
DamdimopoulosAE, Miranda-VizueteA, Pelto-HuikkoM, GustafssonJA, SpyrouG. Human mitochondrial thioredoxin. Involvement in mitochondrial membrane potential and cell death. J Biol Chem, 277:33249–33257. 2002.
82.
DasKC. c-Jun NH2-terminal kinase-mediated redox-dependent degradation of IkappaB: role of thioredoxin in NF-kappaB activation. J Biol Chem, 276:4662–4670. 2001.
83.
DasKC, Lewis-MolockY, WhiteCW. Elevation of manganese superoxide dismutase gene expression by thioredoxin. Am J Respir Cell Mol Biol, 17:713–726. 1997.
84.
DattaSR, BrunetA, GreenbergME. Cellular survival: a play in three Akts. Genes Dev, 13:2905–2927. 1999.
85.
De NardoD, LatzE. NLRP3 inflammasomes link inflammation and metabolic disease. Trends Immunol, 32:373–379. 2011.
86.
de RijkMC, LaunerLJ, BergerK, BretelerMM, DartiguesJF, BaldereschiM, FratiglioniL, LoboA, Martinez-LageJ, TrenkwalderC, HofmanA. Prevalence of Parkinson's disease in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology, 54:S21–S23. 2000.
87.
DerooBJ, HewittSC, PeddadaSD, KorachKS. Estradiol regulates the thioredoxin antioxidant system in the mouse uterus. Endocrinology, 145:5485–5492. 2004.
88.
DesseinAJ, LenziHL, BinaJC, CarvalhoEM, WeiserWY, AndradeZA, DavidJR. Modulation of eosinophil cytotoxicity by blood mononuclear cells from healthy subjects and patients with chronic schistosomiasis mansoni. Cell Immunol, 85:100–113. 1984.
89.
DeviTS, LeeI, HuttemannM, KumarA, NantwiKD, SinghLP. TXNIP links innate host defense mechanisms to oxidative stress and inflammation in retinal Muller glia under chronic hyperglycemia: implications for diabetic retinopathy. Exp Diabetes Res, 2012:438238. 2012.
90.
Di TrapaniG, PerkinsA, ClarkeF. Production and secretion of thioredoxin from transformed human trophoblast cells. Mol Hum Reprod, 4:369–375. 1998.
91.
DinarelloCA. Interleukin-1 beta, interleukin-18, and the interleukin-1 beta converting enzyme. Ann N Y Acad Sci, 856:1–11. 1998.
92.
DrevetJR. The antioxidant glutathione peroxidase family and spermatozoa: a complex story. Mol Cell Endocrinol, 250:70–79. 2006.
93.
DrogeW. Free radicals in the physiological control of cell function. Physiol Rev, 82:47–95. 2002.
94.
DuttaKK, NishinakaY, MasutaniH, AkatsukaS, AungTT, ShiraseT, LeeWH, YamadaY, HiaiH, YodoiJ, ToyokuniS. Two distinct mechanisms for loss of thioredoxin-binding protein-2 in oxidative stress-induced renal carcinogenesis. Lab Invest, 85:798–807. 2005.
95.
DyeRV, MillerKJ, SingerEJ, LevineAJ. Hormone replacement therapy and risk for neurodegenerative diseases. Int J Alzheimers Dis, 2012:258454. 2012.
96.
EganME, PearsonM, WeinerSA, RajendranV, RubinD, Glockner-PagelJ, CannyS, DuK, LukacsGL, CaplanMJ. Curcumin, a major constituent of turmeric, corrects cystic fibrosis defects. Science, 304:600–602. 2004.
97.
El HadriK, MahmoodDF, CouchieD, Jguirim-SouissiI, GenzeF, DiderotV, SyrovetsT, LunovO, SimmetT, RouisM. Thioredoxin-1 promotes anti-inflammatory macrophages of the M2 phenotype and antagonizes atherosclerosis. Arterioscler Thromb Vasc Biol, 32:1445–1452. 2012.
98.
ElgortMG, O'SheaJM, JiangY, AyerDE. Transcriptional and translational downregulation of thioredoxin interacting protein is required for metabolic reprogramming during G(1)Genes Cancer, 1:893–907. 2010.
99.
EmaM, HirotaK, MimuraJ, AbeH, YodoiJ, SogawaK, PoellingerL, Fujii-KuriyamaY. Molecular mechanisms of transcription activation by HLF and HIF1alpha in response to hypoxia: their stabilization and redox signal-induced interaction with CBP/p300. EMBO J, 18:1905–1914. 1999.
100.
EngmanL, Al-MaharikN, McNaughtonM, BirminghamA, PowisG. Thioredoxin reductase and cancer cell growth inhibition by organotellurium antioxidants. Anticancer Drugs, 14:153–161. 2003.
101.
EricsonML, HorlingJ, Wendel-HansenV, HolmgrenA, RosenA. Secretion of thioredoxin after in vitro activation of human B cells. Lymphokine Cytokine Res, 11:201–207. 1992.
FangJ, LuJ, HolmgrenA. Thioredoxin reductase is irreversibly modified by curcumin: a novel molecular mechanism for its anticancer activity. J Biol Chem, 280:25284–25290. 2005.
104.
FangJ, NakamuraT, ChoDH, GuZ, LiptonSA. S-nitrosylation of peroxiredoxin 2 promotes oxidative stress-induced neuronal cell death in Parkinson's disease. Proc Natl Acad Sci U S A, 104:18742–18747. 2007.
105.
FehrenbachE, NiessAM. Role of heat shock proteins in the exercise response. Exerc Immunol Rev, 5:57–77. 1999.
106.
FerdinandyP. Myocardial ischaemia/reperfusion injury and preconditioning: effects of hypercholesterolaemia/hyperlipidaemia. Br J Pharmacol, 138:283–285. 2003.
107.
FesusL, PiacentiniM. Transglutaminase 2: an enigmatic enzyme with diverse functions. Trends Biochem Sci, 27:534–539. 2002.
108.
FiresteinGS. Invasive fibroblast-like synoviocytes in rheumatoid arthritis. Passive responders or transformed aggressors?Arthritis Rheum, 39:1781–1790. 1996.
109.
FishelsonL, BaranesA. Morphological and cytological ontogenesis of the ampullae of lorenzini and lateral line canals in the Oman shark, Iago omanensis Norman 1939 (Triakidae), from the Gulf of Aqaba, Red Sea. Anat Rec, 252:532–545. 1998.
110.
FloheL, Brigelius-FloheR, SaliouC, TraberMG, PackerL. Redox regulation of NF-kappa B activation. Free Radic Biol Med, 22:1115–1126. 1997.
111.
FolkertsG, NijkampFP. Airway epithelium: more than just a barrier!Trends Pharmacol Sci, 19:334–341. 1998.
ForstermannU. Nitric oxide and oxidative stress in vascular disease. Pflugers Arch, 459:923–939. 2010.
114.
FosterMW, HessDT, StamlerJS. Protein S-nitrosylation in health and disease: a current perspective. Trends Mol Med, 15:391–404. 2009.
115.
FranchiL. Role of inflammasomes in salmonella infection. Front Microbiol, 2:8. 2011.
116.
FreemermanAJ, GallegosA, PowisG. Nuclear factor kappaB transactivation is increased but is not involved in the proliferative effects of thioredoxin overexpression in MCF-7 breast cancer cells. Cancer Res, 59:4090–4094. 1999.
117.
FuC, WuC, LiuT, AgoT, ZhaiP, SadoshimaJ, LiH. Elucidation of thioredoxin target protein networks in mouse. Mol Cell Proteomics, 8:1674–1687. 2009.
118.
FukuseT, HirataT, YokomiseH, HasegawaS, InuiK, MitsuiA, HirakawaT, HitomiS, YodoiJ, WadaH. Attenuation of ischaemia reperfusion injury by human thioredoxin. Thorax, 50:387–391. 1995.
119.
FusterV, KellyBB, VedanthanR. Global cardiovascular health urgent need for an intersectoral approach. J Am Coll Cardiol, 58:1208–1210. 2011.
120.
GalkinaE, LeyK. Immune and inflammatory mechanisms of atherosclerosis (*)Annu Rev Immunol, 27:165–197. 2009.
GasconE, GaoFB. Cause or effect: misregulation of microRNA pathways in neurodegeneration. Front Neurosci, 6:48. 2012.
123.
GasdaskaPY, OblongJE, CotgreaveIA, PowisG. The predicted amino acid sequence of human thioredoxin is identical to that of the autocrine growth factor human adult T-cell derived factor (ADF): thioredoxin mRNA is elevated in some human tumors. Biochim Biophys Acta, 1218:292–296. 1994.
GayS, GayRE, KoopmanWJ. Molecular and cellular mechanisms of joint destruction in rheumatoid arthritis: two cellular mechanisms explain joint destruction?Ann Rheum Dis, 52,Suppl 1:S39–S47. 1993.
126.
GhoshN, GhoshR, MandalSC. Antioxidant protection: a promising therapeutic intervention in neurodegenerative disease. Free Radic Res, 45:888–905. 2011.
127.
GielenS, AdamsV, Mobius-WinklerS, LinkeA, ErbsS, YuJ, KempfW, SchubertA, SchulerG, HambrechtR. Anti-inflammatory effects of exercise training in the skeletal muscle of patients with chronic heart failure. J Am Coll Cardiol, 42:861–868. 2003.
128.
Gil-BeaF, AkterinS, PerssonT, MateosL, SandebringA, Avila-CarinoJ, Gutierrez-RodriguezA, SundstromE, HolmgrenA, WinbladB, Cedazo-MinguezA. Thioredoxin-80 is a product of alpha-secretase cleavage that inhibits amyloid-beta aggregation and is decreased in Alzheimer's disease brain. EMBO Mol Med, 4:1097–1111. 2012.
129.
GladyshevVN, JeangKT, StadtmanTC. Selenocysteine, identified as the penultimate C-terminal residue in human T-cell thioredoxin reductase, corresponds to TGA in the human placental gene. Proc Natl Acad Sci U S A, 93:6146–6151. 1996.
130.
GoYM, HalveyPJ, HansenJM, ReedM, PohlJ, JonesDP. Reactive aldehyde modification of thioredoxin-1 activates early steps of inflammation and cell adhesion. Am J Pathol, 171:1670–1681. 2007.
131.
GoYM, JonesDP. Redox control systems in the nucleus: mechanisms and functions. Antioxid Redox Signal, 13:489–509. 2010.
132.
GoelA, KunnumakkaraAB, AggarwalBB. Curcumin as “Curecumin”: from kitchen to clinic. Biochem Pharmacol, 75:787–809. 2008.
133.
GornerK, HoltorfE, WaakJ, PhamTT, Vogt-WeisenhornDM, WurstW, HaassC, KahlePJ. Structural determinants of the C-terminal helix-kink-helix motif essential for protein stability and survival promoting activity of DJ-1. J Biol Chem, 282:13680–13691. 2007.
134.
GreerEL, OskouiPR, BankoMR, ManiarJM, GygiMP, GygiSP, BrunetA. The energy sensor AMP-activated protein kinase directly regulates the mammalian FOXO3 transcription factor. J Biol Chem, 282:30107–30119. 2007.
135.
GriffinMD, LutzW, PhanVA, BachmanLA, McKeanDJ, KumarR. Dendritic cell modulation by 1alpha,25 dihydroxyvitamin D3 and its analogs: a vitamin D receptor-dependent pathway that promotes a persistent state of immaturity in vitro and in vivo. Proc Natl Acad Sci U S A, 98:6800–6805. 2001.
136.
GrippoJF, HolmgrenA, PrattWB. Proof that the endogenous, heat-stable glucocorticoid receptor-activating factor is thioredoxin. J Biol Chem, 260:93–97. 1985.
137.
GromerS, ArscottLD, WilliamsCHJr., SchirmerRH, BeckerK. Human placenta thioredoxin reductase. Isolation of the selenoenzyme, steady state kinetics, and inhibition by therapeutic gold compounds. J Biol Chem, 273:20096–20101. 1998.
138.
GromerS, UrigS, BeckerK. The thioredoxin system—from science to clinic. Med Res Rev, 24:40–89. 2004.
139.
GulbinsE, LiPL. Physiological and pathophysiological aspects of ceramide. Am J Physiol Regul Integr Comp Physiol, 290:R11–R26. 2006.
140.
HaapasaloH, KylaniemiM, PaunulN, KinnulaVL, SoiniY. Expression of antioxidant enzymes in astrocytic brain tumors. Brain Pathol, 13:155–164. 2003.
141.
HabuS, FukuiH, ShimamuraK, KasaiM, NagaiY, OkumuraK, TamaokiN. In vivo effects of anti-asialo GM1. I. Reduction of NK activity and enhancement of transplanted tumor growth in nude mice. J Immunol, 127:34–38. 1981.
142.
HadriKE, MahmoodDF, CouchieD, Jguirim-SouissiI, GenzeF, DiderotV, SyrovetsT, LunovO, SimmetT, RouisM. Thioredoxin-1 promotes anti-inflammatory macrophages of the m2 phenotype and antagonizes atherosclerosis. Arterioscler Thromb Vasc Biol, 32:1445–1452. 2012.
143.
HaendelerJ. Thioredoxin-1 and posttranslational modifications. Antioxid Redox Signal, 8:1723–1728. 2006.
144.
HaendelerJ, HoffmannJ, TischlerV, BerkBC, ZeiherAM, DimmelerS. Redox regulatory and anti-apoptotic functions of thioredoxin depend on S-nitrosylation at cysteine 69. Nat Cell Biol, 4:743–749. 2002.
145.
HallA, NelsonK, PooleLB, KarplusPA. Structure-based insights into the catalytic power and conformational dexterity of peroxiredoxins. Antioxid Redox Signal, 15:795–815. 2011.
146.
HallG, EmsleyJ. Structure of human thioredoxin exhibits a large conformational change. Protein Sci, 19:1807–1811. 2010.
147.
HamadaY, FujiiH, KitazawaR, YodoiJ, KitazawaS, FukagawaM. Thioredoxin-1 overexpression in transgenic mice attenuates streptozotocin-induced diabetic osteopenia: a novel role of oxidative stress and therapeutic implications. Bone, 44:936–941. 2009.
148.
HamadaY, FukagawaM. A possible role of thioredoxin interacting protein in the pathogenesis of streptozotocin-induced diabetic nephropathy. Kobe J Med Sci, 53:53–61. 2007.
149.
HamadaY, MiyataS, Nii-KonoT, KitazawaR, KitazawaS, HigoS, FukunagaM, UeyamaS, NakamuraH, YodoiJ, FukagawaM, KasugaM. Overexpression of thioredoxin1 in transgenic mice suppresses development of diabetic nephropathy. Nephrol Dial Transplant, 22:1547–1557. 2007.
HanYM, ShinDS, LeeYJ, IsmailIA, HongSH, HanDC, KwonBM. 2-Hydroxycurcuminoid induces apoptosis of human tumor cells through the reactive oxygen species-mitochondria pathway. Bioorg Med Chem Lett, 21:747–751. 2011.
152.
HansenJM, WatsonWH, JonesDP. Compartmentation of Nrf-2 redox control: regulation of cytoplasmic activation by glutathione and DNA binding by thioredoxin-1. Toxicol Sci, 82:308–317. 2004.
153.
HanssonGK, LibbyP, SchonbeckU, YanZQ. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ Res, 91:281–291. 2002.
154.
HarmonJS, SteinR, RobertsonRP. Oxidative stress-mediated, post-translational loss of MafA protein as a contributing mechanism to loss of insulin gene expression in glucotoxic beta cells. J Biol Chem, 280:11107–11113. 2005.
155.
HashemySI, HolmgrenA. Regulation of the catalytic activity and structure of human thioredoxin 1 via oxidation and S-nitrosylation of cysteine residues. J Biol Chem, 283:21890–21898. 2008.
156.
HashemySI, UngerstedtJS, Zahedi AvvalF, HolmgrenA. Motexafin gadolinium, a tumor-selective drug targeting thioredoxin reductase and ribonucleotide reductase. J Biol Chem, 281:10691–10697. 2006.
157.
HatcherH, PlanalpR, ChoJ, TortiFM, TortiSV. Curcumin: from ancient medicine to current clinical trials. Cell Mol Life Sci, 65:1631–1652. 2008.
158.
HattoriI, TakagiY, NakamuraH, NozakiK, BaiJ, KondoN, SuginoT, NishimuraM, HashimotoN, YodoiJ. Intravenous administration of thioredoxin decreases brain damage following transient focal cerebral ischemia in mice. Antioxid Redox Signal, 6:81–87. 2004.
159.
HayashiS, Hajiro-NakanishiK, MakinoY, EguchiH, YodoiJ, TanakaH. Functional modulation of estrogen receptor by redox state with reference to thioredoxin as a mediator. Nucleic Acids Res, 25:4035–4040. 1997.
160.
HedleyD, PintilieM, WooJ, NickleeT, MorrisonA, BirleD, FylesA, MilosevicM, HillR. Up-regulation of the redox mediators thioredoxin and apurinic/apyrimidinic excision (APE)/Ref-1 in hypoxic microregions of invasive cervical carcinomas, mapped using multispectral, wide-field fluorescence image analysis. Am J Pathol, 164:557–565. 2004.
HirotaK, MatsuiM, IwataS, NishiyamaA, MoriK, YodoiJ. AP-1 transcriptional activity is regulated by a direct association between thioredoxin and Ref-1. Proc Natl Acad Sci U S A, 94:3633–3638. 1997.
163.
HirotaK, MurataM, SachiY, NakamuraH, TakeuchiJ, MoriK, YodoiJ. Distinct roles of thioredoxin in the cytoplasm and in the nucleus. A two-step mechanism of redox regulation of transcription factor NF-kappaB. J Biol Chem, 274:27891–27897. 1999.
164.
HoferS, RosenhagenC, NakamuraH, YodoiJ, BoppC, ZimmermannJB, GoebelM, SchemmerP, HoffmannK, Schulze-OsthoffK, BreitkreutzR, WeigandMA. Thioredoxin in human and experimental sepsis. Crit Care Med, 37:2155–2159. 2009.
165.
HolmgrenA. Thioredoxin. Annu Rev Biochem, 54:237–271. 1985.
166.
HolmgrenA, LuJ. Thioredoxin and thioredoxin reductase: current research with special reference to human disease. Biochem Biophys Res Commun, 396:120–124. 2010.
167.
HornungV, BauernfeindF, HalleA, SamstadEO, KonoH, RockKL, FitzgeraldKA, LatzE. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat Immunol, 9:847–856. 2008.
168.
HoshidaS, NishidaM, YamashitaN, IgarashiJ, HoriM, KamadaT, KuzuyaT, TadaM. Amelioration of severity of myocardial injury by a nitric oxide donor in rabbits fed a cholesterol-rich diet. J Am Coll Cardiol, 27:902–909. 1996.
169.
HottaM, TashiroF, IkegamiH, NiwaH, OgiharaT, YodoiJ, MiyazakiJ. Pancreatic beta cell-specific expression of thioredoxin, an antioxidative and antiapoptotic protein, prevents autoimmune and streptozotocin-induced diabetes. J Exp Med, 188:1445–1451. 1998.
170.
HuJW, WangJ, XuM, ShuYF, KongWX, ShengHX, ZhangB, ChenH. [Construction and expression of recombinant adenovirus vector Ad5-hTRX-EGFP]Zhongguo Shi Yan Xue Ye Xue Za Zhi, 20:744–748. 2012.
171.
HuX, WengZ, ChuCT, ZhangL, CaoG, GaoY, SignoreA, ZhuJ, HastingsT, GreenamyreJT, ChenJ. Peroxiredoxin-2 protects against 6-hydroxydopamine-induced dopaminergic neurodegeneration via attenuation of the apoptosis signal-regulating kinase (ASK1) signaling cascade. J Neurosci, 31:247–261. 2011.
172.
HuiTY, ShethSS, DiffleyJM, PotterDW, LusisAJ, AttieAD, DavisRA. Mice lacking thioredoxin-interacting protein provide evidence linking cellular redox state to appropriate response to nutritional signals. J Biol Chem, 279:24387–24393. 2004.
173.
HungLW, VillemagneVL, ChengL, SherrattNA, AytonS, WhiteAR, CrouchPJ, LimS, LeongSL, WilkinsS, GeorgeJ, RobertsBR, PhamCL, LiuX, ChiuFC, ShacklefordDM, PowellAK, MastersCL, BushAI, O'KeefeG, CulvenorJG, CappaiR, ChernyRA, DonnellyPS, HillAF, FinkelsteinDI, BarnhamKJ. The hypoxia imaging agent CuII(atsm) is neuroprotective and improves motor and cognitive functions in multiple animal models of Parkinson's disease. J Exp Med, 209:837–854. 2012.
174.
HusbeckB, StringerDE, GernerEW, PowisG. Increased thioredoxin-1 inhibits SSAT expression in MCF-7 human breast cancer cells. Biochem Biophys Res Commun, 306:469–475. 2003.
175.
HwangCY, RyuYS, ChungMS, KimKD, ParkSS, ChaeSK, ChaeHZ, KwonKS. Thioredoxin modulates activator protein 1 (AP-1) activity and p27Kip1 degradation through direct interaction with Jab1. Oncogene, 23:8868–8875. 2004.
176.
IchikiH, HoshinoT, KinoshitaT, ImaokaH, KatoS, InoueH, NakamuraH, YodoiJ, YoungHA, AizawaH. Thioredoxin suppresses airway hyperresponsiveness and airway inflammation in asthma. Biochem Biophys Res Commun, 334:1141–1148. 2005.
177.
ImJY, LeeKW, WooJM, JunnE, MouradianMM. DJ-1 induces thioredoxin 1 expression through the Nrf2 pathway. Hum Mol Genet, 21:3013–3024. 2012.
178.
ImaokaH, HoshinoT, TakeiS, SakazakiY, KinoshitaT, OkamotoM, KawayamaT, YodoiJ, KatoS, IwanagaT, AizawaH. Effects of thioredoxin on established airway remodeling in a chronic antigen exposure asthma model. Biochem Biophys Res Commun, 360:525–530. 2007.
179.
InomataY, TaniharaH, TanitoM, OkuyamaH, HoshinoY, KinumiT, KawajiT, KondoN, YodoiJ, NakamuraH. Suppression of choroidal neovascularization by thioredoxin-1 via interaction with complement factor H. Invest Ophthalmol Vis Sci, 49:5118–5125. 2008.
180.
InoueT, WuL, StuartJ, MakiCG. Control of p53 nuclear accumulation in stressed cells. FEBS Lett, 579:4978–4984. 2005.
181.
IshiiY, HiranoK, MorishimaY, MasuyamaK, GotoY, NomuraA, SakamotoT, UchidaY, SagaiM, SekizawaK. Early molecular and cellular events of oxidant-induced pulmonary fibrosis in rats. Toxicol Appl Pharmacol, 167:173–181. 2000.
182.
IsowaN, YoshimuraT, KosakaS, LiuM, HitomiS, YodoiJ, WadaH. Human thioredoxin attenuates hypoxia-reoxygenation injury of murine endothelial cells in a thiol-free condition. J Cell Physiol, 182:33–40. 2000.
183.
ItoW, KobayashiN, TakedaM, UekiS, KayabaH, NakamuraH, YodoiJ, ChiharaJ. Thioredoxin in allergic inflammation. Int Arch Allergy Immunol, 155,Suppl 1:142–146. 2011.
184.
IwasawaS, YamanoY, TakiguchiY, TanzawaH, TatsumiK, UzawaK. Upregulation of thioredoxin reductase 1 in human oral squamous cell carcinoma. Oncol Rep, 25:637–644. 2011.
185.
JangYC, RemmenVH. The mitochondrial theory of aging: insight from transgenic and knockout mouse models. Exp Gerontol, 44:256–260. 2009.
186.
JiJ, PanE, LiJ, ChenJ, CaoJ, SunD, LuX, ChenS, GuD, DuanX, WuX, HuangJ. Classical risk factors of cardiovascular disease among Chinese male steel workers: a prospective cohort study for 20 years. BMC Public Health, 11:497. 2011.
187.
JikimotoT, NishikuboY, KoshibaM, KanagawaS, MorinobuS, MorinobuA, SauraR, MizunoK, KondoS, ToyokuniS, NakamuraH, YodoiJ, KumagaiS. Thioredoxin as a biomarker for oxidative stress in patients with rheumatoid arthritis. Mol Immunol, 38:765–772. 2002.
188.
JimenezA, ZuW, RaweVY, Pelto-HuikkoM, FlickingerCJ, SutovskyP, GustafssonJA, OkoR, Miranda-VizueteA. Spermatocyte/spermatid-specific thioredoxin-3, a novel Golgi apparatus-associated thioredoxin, is a specific marker of aberrant spermatogenesis. J Biol Chem, 279:34971–34982. 2004.
JinS, ZhangY, YiF, LiPL. Critical role of lipid raft redox signaling platforms in endostatin-induced coronary endothelial dysfunction. Arterioscler Thromb Vasc Biol, 28:485–490. 2008.
191.
JinX, StamnaesJ, KloeckC, DiraimondoTR, SollidLM, KhoslaC. Activation of extracellular transglutaminase 2 by thioredoxin. J Biol Chem, 286:37866–37873. 2011.
192.
JohnstonJB, RahmanMM, McFaddenG. Strategies that modulate inflammasomes: insights from host-pathogen interactions. Semin Immunopathol, 29:261–274. 2007.
193.
JunnE, HanSH, ImJY, YangY, ChoEW, UmHD, KimDK, LeeKW, HanPL, RheeSG, ChoiI. Vitamin D3 up-regulated protein 1 mediates oxidative stress via suppressing the thioredoxin function. J Immunol, 164:6287–6295. 2000.
194.
KabuyamaY, KitamuraT, YamakiJ, HommaMK, KikuchiS, HommaY. Involvement of thioredoxin reductase 1 in the regulation of redox balance and viability of rheumatoid synovial cells. Biochem Biophys Res Commun, 367:491–496. 2008.
195.
KaghadM, DessarpsF, Jacquemin-SablonH, CaputD, FradeliziD, WollmanEE. Genomic cloning of human thioredoxin-encoding gene: mapping of the transcription start point and analysis of the promoter. Gene, 140:273–278. 1994.
196.
KahnSE, HullRL, UtzschneiderKM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature, 444:840–846. 2006.
197.
Kaimul AhsanM, NakamuraH, TanitoM, YamadaK, UtsumiH, YodoiJ. Thioredoxin-1 suppresses lung injury and apoptosis induced by diesel exhaust particles (DEP) by scavenging reactive oxygen species and by inhibiting DEP-induced downregulation of Akt. Free Radic Biol Med, 39:1549–1559. 2005.
198.
KaimulAM, NakamuraH, MasutaniH, YodoiJ. Thioredoxin and thioredoxin-binding protein-2 in cancer and metabolic syndrome. Free Radic Biol Med, 43:861–868. 2007.
199.
KaiserN, LeibowitzG, NesherR. Glucotoxicity and beta-cell failure in type 2 diabetes mellitus. J Pediatr Endocrinol Metab, 16:5–22. 2003.
200.
KalininaEV, ChernovNN, SaprinAN. Involvement of thio-, peroxi-, and glutaredoxins in cellular redox-dependent processes. Biochemistry (Mosc), 73:1493–1510. 2008.
201.
KamimotoY, SugiyamaT, KihiraT, ZhangL, MurabayashiN, UmekawaT, NagaoK, MaN, ToyodaN, YodoiJ, SagawaN. Transgenic mice overproducing human thioredoxin-1, an antioxidative and anti-apoptotic protein, prevents diabetic embryopathy. Diabetologia, 53:2046–2055. 2010.
202.
KanetoH, KajimotoY, MiyagawaJ, MatsuokaT, FujitaniY, UmayaharaY, HanafusaT, MatsuzawaY, YamasakiY, HoriM. Beneficial effects of antioxidants in diabetes: possible protection of pancreatic beta-cells against glucose toxicity. Diabetes, 48:2398–2406. 1999.
203.
KanterM, AktasC, ErbogaM. Curcumin attenuates testicular damage, apoptotic germ cell death, and oxidative stress in streptozotocin-induced diabetic rats. Mol Nutr Food Res, 2012[Epub ahead of print]DOI:10.1002/mnfr.201200170.
204.
KanterMM, HamlinRL, UnverferthDV, DavisHW, MerolaAJ. Effect of exercise training on antioxidant enzymes and cardiotoxicity of doxorubicin. J Appl Physiol, 59:1298–1303. 1985.
205.
KapakosG, YourevaV, SrivastavaAK. Attenuation of endothelin-1-induced PKB and ERK1/2 signaling, as well as Egr-1 expression, by curcumin in A-10 vascular smooth muscle cells. Can J Physiol Pharmacol, 90:1277–1285. 2012.
206.
KasunoK, NakamuraH, OnoT, MusoE, YodoiJ. Protective roles of thioredoxin, a redox-regulating protein, in renal ischemia/reperfusion injury. Kidney Int, 64:1273–1282. 2003.
207.
KenslerTW, WakabayashiN, BiswalS. Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu Rev Pharmacol Toxicol, 47:89–116. 2007.
208.
KimHJ, ChaeHZ, KimYJ, KimYH, HwangsTS, ParkEM, ParkYM. Preferential elevation of Prx I and Trx expression in lung cancer cells following hypoxia and in human lung cancer tissues. Cell Biol Toxicol, 19:285–298. 2003.
KimSH, OhJ, ChoiJY, JangJY, KangMW, LeeCE. Identification of human thioredoxin as a novel IFN-gamma-induced factor: mechanism of induction and its role in cytokine production. BMC Immunol, 9:64. 2008.
212.
KimSR, LeeKS, ParkSJ, MinKH, LeeMH, LeeKA, BartovO, AtlasD, LeeYC. A novel dithiol amide CB3 attenuates allergic airway disease through negative regulation of p38 mitogen-activated protein kinase. Am J Respir Crit Care Med, 183:1015–1024. 2011.
213.
KingBC, NowakowskaJ, KarstenCM, KohlJ, RenstromE, BlomAM. Truncated and full-length thioredoxin-1 have opposing activating and inhibitory properties for human complement with relevance to endothelial surfaces. J Immunol, 188:4103–4112. 2012.
214.
KirkpatrickDL, KuperusM, DowdeswellM, PotierN, DonaldLJ, KunkelM, BerggrenM, AnguloM, PowisG. Mechanisms of inhibition of the thioredoxin growth factor system by antitumor 2-imidazolyl disulfides. Biochem Pharmacol, 55:987–994. 1998.
KondoN, NakamuraH, MasutaniH, YodoiJ. Redox regulation of human thioredoxin network. Antioxid Redox Signal, 8:1881–1890. 2006.
220.
KuoCL, WuSY, IpSW, WuPP, YuCS, YangJS, ChenPY, WuSH, ChungJG. Apoptotic death in curcumin-treated NPC-TW 076 human nasopharyngeal carcinoma cells is mediated through the ROS, mitochondrial depolarization and caspase-3-dependent signaling responses. Int J Oncol, 39:319–328. 2011.
221.
LamokeF, RipandelliG, WebsterS, MontemariA, MaraschiA, MartinP, MarcusDM, LiouGI, BartoliM. Loss of thioredoxin function in retinas of mice overexpressing amyloid beta. Free Radic Biol Med, 53:577–588. 2012.
222.
LappalainenZ, LappalainenJ, OksalaNK, LaaksonenDE, KhannaS, SenCK, AtalayM. Diabetes impairs exercise training-associated thioredoxin response and glutathione status in rat brain. J Appl Physiol, 106:461–467. 2009.
223.
LaurentTC, MooreEC, ReichardP. Enzymatic synthesis of deoxyribonucleotides. Iv. isolation and characterization of thioredoxin, the hydrogen donor from Escherichia coli B. J Biol Chem, 239:3436–3444. 1964.
224.
LeafDA, KleinmanMT, HamiltonM, DeitrickRW. The exercise-induced oxidative stress paradox: the effects of physical exercise training. Am J Med Sci, 317:295–300. 1999.
225.
LeeHC, WeiYH. Oxidative stress, mitochondrial DNA mutation, and apoptosis in aging. Exp Biol Med (Maywood), 232:592–606. 2007.
226.
LeeSR, YangKS, KwonJ, LeeC, JeongW, RheeSG. Reversible inactivation of the tumor suppressor PTEN by H2O2. J Biol Chem, 277:20336–20342. 2002.
227.
LeibowitzG, BacharE, ShakedM, SinaiA, Ketzinel-GiladM, CerasiE, KaiserN. Glucose regulation of beta-cell stress in type 2 diabetes. Diabetes Obes Metab, 12,Suppl 2:66–75. 2010.
228.
LemarechalH, AllanoreY, Chenevier-GobeauxC, EkindjianOG, KahanA, BorderieD. High redox thioredoxin but low thioredoxin reductase activities in the serum of patients with rheumatoid arthritis. Clin Chim Acta, 367:156–161. 2006.
229.
LemarechalH, AnractP, BeaudeuxJL, Bonnefont-RousselotD, EkindjianOG, BorderieD. Expression and extracellular release of Trx80, the truncated form of thioredoxin, by TNF-alpha- and IL-1beta-stimulated human synoviocytes from patients with rheumatoid arthritis. Clin Sci (Lond), 113:149–155. 2007.
230.
LemarechalH, AnractP, BeaudeuxJL, Bonnefont-RousselotD, EkindjianOG, BorderieD. Impairment of thioredoxin reductase activity by oxidative stress in human rheumatoid synoviocytes. Free Radic Res, 41:688–698. 2007.
231.
LenziHL, MednisAD, DesseinAJ. Activation of human eosinophils by monokines and lymphokines: source and biochemical characteristics of the eosinophil cytotoxicity-enhancing activity produced by blood mononuclear cells. Cell Immunol, 94:333–346. 1985.
232.
LeslieNR, BennettD, LindsayYE, StewartH, GrayA, DownesCP. Redox regulation of PI 3-kinase signalling via inactivation of PTEN. EMBO J, 22:5501–5510. 2003.
233.
LiAC, GlassCK. The macrophage foam cell as a target for therapeutic intervention. Nat Med, 8:1235–1242. 2002.
234.
LiXN, SongJ, ZhangL, LeMaireSA, HouX, ZhangC, CoselliJS, ChenL, WangXL, ZhangY, ShenYH. Activation of the AMPK-FOXO3 pathway reduces fatty acid-induced increase in intracellular reactive oxygen species by upregulating thioredoxin. Diabetes, 58:2246–2257. 2009.
235.
LibbyP. Inflammation in atherosclerosis. Nature, 420:868–874. 2002.
236.
LibbyP, OkamotoY, RochaVZ, FolcoE. Inflammation in atherosclerosis: transition from theory to practice. Circ J, 74:213–220. 2010.
LilligCH, HolmgrenA. Thioredoxin and related molecules—from biology to health and disease. Antioxid Redox Signal, 9:25–47. 2007.
239.
LincolnDT, Al-YatamaF, MohammedFM, Al-BanawAG, Al-BaderM, BurgeM, SinowatzF, SingalPK. Thioredoxin and thioredoxin reductase expression in thyroid cancer depends on tumour aggressiveness. Anticancer Res, 30:767–775. 2010.
240.
LincolnDT, Ali EmadiEM, TonissenKF, ClarkeFM. The thioredoxin-thioredoxin reductase system: over-expression in human cancer. Anticancer Res, 23:2425–2433. 2003.
LiuW, NakamuraH, ShiojiK, TanitoM, OkaS, AhsanMK, SonA, IshiiY, KishimotoC, YodoiJ. Thioredoxin-1 ameliorates myosin-induced autoimmune myocarditis by suppressing chemokine expressions and leukocyte chemotaxis in mice. Circulation, 110:1276–1283. 2004.
243.
LiuY, MinW. Thioredoxin promotes ASK1 ubiquitination and degradation to inhibit ASK1-mediated apoptosis in a redox activity-independent manner. Circ Res, 90:1259–1266. 2002.
244.
LopezAD, MathersCD, EzzatiM, JamisonDT, MurrayCJ. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet, 367:1747–1757. 2006.
LowesDA, GalleyHF. Mitochondrial protection by the thioredoxin-2 and glutathione systems in an in vitro endothelial model of sepsis. Biochem J, 436:123–132. 2011.
247.
LuJ, ChewEH, HolmgrenA. Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide. Proc Natl Acad Sci U S A, 104:12288–12293. 2007.
248.
LuJ, HolmgrenA. Thioredoxin system in cell death progression. Antioxid Redox Signal, 17:1738–1747. 2012.
249.
LuJ, PappLV, FangJ, Rodriguez-NietoS, ZhivotovskyB, HolmgrenA. Inhibition of Mammalian thioredoxin reductase by some flavonoids: implications for myricetin and quercetin anticancer activity. Cancer Res, 66:4410–4418. 2006.
MadamanchiNR, HakimZS, RungeMS. Oxidative stress in atherogenesis and arterial thrombosis: the disconnect between cellular studies and clinical outcomes. J Thromb Haemost, 3:254–267. 2005.
MadeiraJM, GibsonDL, KeanWF, KlegerisA. The biological activity of auranofin: implications for novel treatment of diseases. Inflammopharmacology, 20:297–306. 2012.
254.
MakS, NewtonGE. The oxidative stress hypothesis of congestive heart failure: radical thoughts. Chest, 120:2035–2046. 2001.
255.
MakinoY, OkamotoK, YoshikawaN, AoshimaM, HirotaK, YodoiJ, UmesonoK, MakinoI, TanakaH. Thioredoxin: a redox-regulating cellular cofactor for glucocorticoid hormone action. Cross talk between endocrine control of stress response and cellular antioxidant defense system. J Clin Invest, 98:2469–2477. 1996.
256.
MakinoY, YoshikawaN, OkamotoK, HirotaK, YodoiJ, MakinoI, TanakaH. Direct association with thioredoxin allows redox regulation of glucocorticoid receptor function. J Biol Chem, 274:3182–3188. 1999.
MariathasanS, MonackDM. Inflammasome adaptors and sensors: intracellular regulators of infection and inflammation. Nat Rev Immunol, 7:31–40. 2007.
260.
MarksPA, JiangX. Histone deacetylase inhibitors in programmed cell death and cancer therapy. Cell Cycle, 4:549–551. 2005.
261.
MartindaleJL, HolbrookNJ. Cellular response to oxidative stress: signaling for suicide and survival. J Cell Physiol, 192:1–15. 2002.
262.
Martinez-PinnaR, LindholtJS, Blanco-ColioLM, DejouvencelT, Madrigal-MatuteJ, Ramos-MozoP, Vega de CenigaM, MichelJB, EgidoJ, MeilhacO, Martin-VenturaJL. Increased levels of thioredoxin in patients with abdominal aortic aneurysms (AAAs). A potential link of oxidative stress with AAA evolution. Atherosclerosis, 212:333–338. 2010.
263.
MartinezFO, HelmingL, GordonS. Alternative activation of macrophages: an immunologic functional perspective. Annu Rev Immunol, 27:451–483. 2009.
MarumotoM, SuzukiS, HosonoA, ArakawaK, ShibataK, FukuM, GotoC, TokudomeY, HoshinoH, ImaedaN, KobayashiM, YodoiJ, TokudomeS. Changes in thioredoxin concentrations: an observation in an ultra-marathon race. Environ Health Prev Med, 15:129–134. 2010.
266.
MasutaniH, BaiJ, KimYC, YodoiJ. Thioredoxin as a neurotrophic cofactor and an important regulator of neuroprotection. Mol Neurobiol, 29:229–242. 2004.
267.
MasutaniH, OtsukiR, YamaguchiY, TakenakaM, KanohN, TakateraK, KunimotoY, YodoiJ. Fragrant unsaturated aldehydes elicit activation of the Keap1/Nrf2 system leading to the upregulation of thioredoxin expression and protection against oxidative stress. Antioxid Redox Signal, 11:949–962. 2009.
268.
MatsuiM, OshimaM, OshimaH, TakakuK, MaruyamaT, YodoiJ, TaketoMM. Early embryonic lethality caused by targeted disruption of the mouse thioredoxin gene. Dev Biol, 178:179–185. 1996.
269.
MatsushimaS, ZablockiD, SadoshimaJ. Application of recombinant thioredoxin1 for treatment of heart disease. J Mol Cell Cardiol, 51:570–573. 2011.
270.
MatsuzawaA, SaegusaK, NoguchiT, SadamitsuC, NishitohH, NagaiS, KoyasuS, MatsumotoK, TakedaK, IchijoH. ROS-dependent activation of the TRAF6-ASK1-p38 pathway is selectively required for TLR4-mediated innate immunity. Nat Immunol, 6:587–592. 2005.
271.
MauBL, PowisG. Inhibition of cellular thioredoxin reductase by diaziquone and doxorubicin. Relationship to the inhibition of cell proliferation and decreased ribonucleotide reductase activity. Biochem Pharmacol, 43:1621–1627. 1992.
272.
MaulikN, DasDK. Emerging potential of thioredoxin and thioredoxin interacting proteins in various disease conditions. Biochim Biophys Acta, 1780:1368–1382. 2008.
273.
MauriceMM, NakamuraH, GringhuisS, OkamotoT, YoshidaS, KullmannF, LechnerS, van der VoortEA, LeowA, VersendaalJ, Muller-LadnerU, YodoiJ, TakPP, BreedveldFC, VerweijCL. Expression of the thioredoxin-thioredoxin reductase system in the inflamed joints of patients with rheumatoid arthritis. Arthritis Rheum, 42:2430–2439. 1999.
274.
MayJM, MendirattaS, HillKE, BurkRF. Reduction of dehydroascorbate to ascorbate by the selenoenzyme thioredoxin reductase. J Biol Chem, 272:22607–22610. 1997.
275.
McCommisKS, McGeeAM, LaughlinMH, BowlesDK, BainesCP. Hypercholesterolemia increases mitochondrial oxidative stress and enhances the MPT response in the porcine myocardium: beneficial effects of chronic exercise. Am J Physiol Regul Integr Comp Physiol, 301:R1250–R1258. 2011.
276.
MengCQ. Inflammation in atherosclerosis: new opportunities for drug discovery. Mini Rev Med Chem, 5:33–40. 2005.
277.
MenuP, PellegrinM, AubertJF, BouzoureneK, TardivelA, MazzolaiL, TschoppJ. Atherosclerosis in ApoE-deficient mice progresses independently of the NLRP3 inflammasome. Cell Death Dis, 2:e137. 2011.
278.
MeuilletEJ, MahadevanD, BerggrenM, CoonA, PowisG. Thioredoxin-1 binds to the C2 domain of PTEN inhibiting PTEN's lipid phosphatase activity and membrane binding: a mechanism for the functional loss of PTEN's tumor suppressor activity. Arch Biochem Biophys, 429:123–133. 2004.
279.
MikkelsenRB, WardmanP. Biological chemistry of reactive oxygen and nitrogen and radiation-induced signal transduction mechanisms. Oncogene, 22:5734–5754. 2003.
280.
MillerS, WalkerSW, ArthurJR, LewinMH, PickardK, NicolF, HowieAF, BeckettGJ. Selenoprotein expression in endothelial cells from different human vasculature and species. Biochim Biophys Acta, 1588:85–93. 2002.
281.
MinnAH, HafeleC, ShalevA. Thioredoxin-interacting protein is stimulated by glucose through a carbohydrate response element and induces beta-cell apoptosis. Endocrinology, 146:2397–2405. 2005.
MitchellDA, MarlettaMA. Thioredoxin catalyzes the S-nitrosation of the caspase-3 active site cysteine. Nat Chem Biol, 1:154–158. 2005.
285.
MitchellDA, MortonSU, FernhoffNB, MarlettaMA. Thioredoxin is required for S-nitrosation of procaspase-3 and the inhibition of apoptosis in Jurkat cells. Proc Natl Acad Sci U S A, 104:11609–11614. 2007.
286.
MitsuiA, HamuroJ, NakamuraH, KondoN, HirabayashiY, Ishizaki-KoizumiS, HirakawaT, InoueT, YodoiJ. Overexpression of human thioredoxin in transgenic mice controls oxidative stress and life span. Antioxid Redox Signal, 4:693–696. 2002.
287.
MochizukiM, KwonYW, YodoiJ, MasutaniH. Thioredoxin regulates cell cycle via the ERK1/2-cyclin D1 pathway. Antioxid Redox Signal, 11:2957–2971. 2009.
288.
MougiakakosD, JohanssonCC, JitschinR, BottcherM, KiesslingR. Increased thioredoxin-1 production in human naturally occurring regulatory T cells confers enhanced tolerance to oxidative stress. Blood, 117:857–861. 2011.
289.
MukherjeeA, MartinSG. The thioredoxin system: a key target in tumour and endothelial cells. Br J Radiol 81 Spec No, 1:S57–S68. 2008.
290.
MukherjeeA, WestwellAD, BradshawTD, StevensMF, CarmichaelJ, MartinSG. Cytotoxic and antiangiogenic activity of AW464 (NSC 706704), a novel thioredoxin inhibitor: an in vitro study. Br J Cancer, 92:350–358. 2005.
NaikE, DixitVM. Modulation of inflammasome activity for the treatment of auto-inflammatory disorders. J Clin Immunol, 30:485–490. 2010.
294.
NakamuraH, De RosaSC, YodoiJ, HolmgrenA, GhezziP, HerzenbergLA, HerzenbergLA. Chronic elevation of plasma thioredoxin: inhibition of chemotaxis and curtailment of life expectancy in AIDS. Proc Natl Acad Sci U S A, 98:2688–2693. 2001.
295.
NakamuraH, HerzenbergLA, BaiJ, ArayaS, KondoN, NishinakaY, HerzenbergLA, YodoiJ. Circulating thioredoxin suppresses lipopolysaccharide-induced neutrophil chemotaxis. Proc Natl Acad Sci U S A, 98:15143–15148. 2001.
296.
NakamuraH, HoshinoY, OkuyamaH, MatsuoY, YodoiJ. Thioredoxin 1 delivery as new therapeutics. Adv Drug Deliv Rev, 61:303–309. 2009.
297.
NakamuraH, MasutaniH, YodoiJ. Extracellular thioredoxin and thioredoxin-binding protein 2 in control of cancer. Semin Cancer Biol, 16:444–451. 2006.
NakamuraH, NakamuraK, YodoiJ. Redox regulation of cellular activation. Annu Rev Immunol, 15:351–369. 1997.
300.
NakamuraH, TamuraS, WatanabeI, IwasakiT, YodoiJ. Enhanced resistancy of thioredoxin-transgenic mice against influenza virus-induced pneumonia. Immunol Lett, 82:165–170. 2002.
301.
NakanishiK, YoshimotoT, TsutsuiH, OkamuraH. Interleukin-18 is a unique cytokine that stimulates both Th1 and Th2 responses depending on its cytokine milieu. Cytokine Growth Factor Rev, 12:53–72. 2001.
302.
NaoiM, MaruyamaW. Monoamine oxidase inhibitors as neuroprotective agents in age-dependent neurodegenerative disorders. Curr Pharm Des, 16:2799–2817. 2010.
303.
NaoiM, MaruyamaW, Inaba-HasegawaK, AkaoY. Type A monoamine oxidase regulates life and death of neurons in neurodegeneration and neuroprotection. Int Rev Neurobiol, 100:85–106. 2011.
304.
NguyenP, AwwadRT, SmartDD, SpitzDR, GiusD. Thioredoxin reductase as a novel molecular target for cancer therapy. Cancer Lett, 236:164–174. 2006.
305.
NguyenT, SherrattPJ, PickettCB. Regulatory mechanisms controlling gene expression mediated by the antioxidant response element. Annu Rev Pharmacol Toxicol, 43:233–260. 2003.
306.
NishinakaY, MasutaniH, NakamuraH, YodoiJ. Regulatory roles of thioredoxin in oxidative stress-induced cellular responses. Redox Rep, 6:289–295. 2001.
NishinakaY, NishiyamaA, MasutaniH, OkaS, AhsanKM, NakayamaY, IshiiY, NakamuraH, MaedaM, YodoiJ. Loss of thioredoxin-binding protein-2/vitamin D3 up-regulated protein 1 in human T-cell leukemia virus type I-dependent T-cell transformation: implications for adult T-cell leukemia leukemogenesis. Cancer Res, 64:1287–1292. 2004.
309.
NishiyamaA, MasutaniH, NakamuraH, NishinakaY, YodoiJ. Redox regulation by thioredoxin and thioredoxin-binding proteins. IUBMB Life, 52:29–33. 2001.
NonnL, WilliamsRR, EricksonRP, PowisG. The absence of mitochondrial thioredoxin 2 causes massive apoptosis, exencephaly, and early embryonic lethality in homozygous mice. Mol Cell Biol, 23:916–922. 2003.
312.
NordbergJ, ArnerES. Reactive oxygen species, antioxidants, and the mammalian thioredoxin system. Free Radic Biol Med, 31:1287–1312. 2001.
313.
Nunez-CordobaJM, Martinez-GonzalezMA. Antioxidant vitamins and cardiovascular disease. Curr Top Med Chem, 11:1861–1869. 2011.
314.
OblongJE, ChantlerEL, GallegosA, KirkpatrickDL, ChenT, MarshallN, PowisG. Reversible inhibition of human thioredoxin reductase activity by cytotoxic alkyl 2-imidazolyl disulfide analogues. Cancer Chemother Pharmacol, 34:434–438. 1994.
315.
OblongJE, GasdaskaPY, SherrillK, PowisG. Purification of human thioredoxin reductase: properties and characterization by absorption and circular dichroism spectroscopy. Biochemistry, 32:7271–7277. 1993.
316.
OhnoS, SatoT, KohuK, TakedaK, OkumuraK, SatakeM, HabuS. Runx proteins are involved in regulation of CD122, Ly49 family and IFN-gamma expression during NK cell differentiation. Int Immunol, 20:71–79. 2008.
317.
OkuyamaH, YoshidaT, SonA, OkaS, WangD, NakayamaR, MasutaniH, NakamuraH, NabeshimaY, YodoiJ. Thioredoxin binding protein 2 modulates natural killer T cell-dependent innate immunity in the liver: possible link to lipid metabolism. Antioxid Redox Signal, 11:2585–2593. 2009.
318.
OnoR, MasakiT, DienS, YuX, FukunagaA, YodoiJ, NishigoriC. Suppressive effect of recombinant human thioredoxin on ultraviolet light-induced inflammation and apoptosis in murine skin. J Dermatol, 39:843–851. 2012.
319.
OsborneSA, HawkesHJ, BaldwinBL, AlexanderKA, SvingenT, ClarkeFM, TonissenKF. The tert-butylhydroquinone-mediated activation of the human thioredoxin gene reveals a novel promoter structure. Biochem J, 398:269–277. 2006.
320.
OsipovRM, BianchiC, FengJ, ClementsRT, LiuY, RobichMP, GlazerHP, SodhaNR, SellkeFW. Effect of hypercholesterolemia on myocardial necrosis and apoptosis in the setting of ischemia-reperfusion. Circulation, 120:S22–S30. 2009.
321.
PapT, Muller-LadnerU, GayRE, GayS. Fibroblast biology. Role of synovial fibroblasts in the pathogenesis of rheumatoid arthritis. Arthritis Res, 2:361–367. 2000.
322.
ParthasarathyS, SantanamN, RamachandranS, MeilhacO. Oxidants and antioxidants in atherogenesis. An appraisal. J Lipid Res, 40:2143–2157. 1999.
323.
PatelJM, HuH, LuL, DeemA, AkindipeO, BrantlyM, BlockER, AntonyVB, BazMA. Thioredoxin as a biomarker for graft rejection in lung transplant recipients. Biomarkers, 13:486–495. 2008.
324.
PatelJM, ZhangJ, BlockER. Nitric oxide-induced inhibition of lung endothelial cell nitric oxide synthase via interaction with allosteric thiols: role of thioredoxin in regulation of catalytic activity. Am J Respir Cell Mol Biol, 15:410–419. 1996.
325.
PatwariP, HigginsLJ, ChutkowWA, YoshiokaJ, LeeRT. The interaction of thioredoxin with Txnip. Evidence for formation of a mixed disulfide by disulfide exchange. J Biol Chem, 281:21884–21891. 2006.
326.
PekkariK, Avila-CarinoJ, BengtssonA, GurunathR, ScheyniusA, HolmgrenA. Truncated thioredoxin (Trx80) induces production of interleukin-12 and enhances CD14 expression in human monocytes. Blood, 97:3184–3190. 2001.
327.
PekkariK, GoodarziMT, ScheyniusA, HolmgrenA, Avila-CarinoJ. Truncated thioredoxin (Trx80) induces differentiation of human CD14+ monocytes into a novel cell type (TAMs) via activation of the MAP kinases p38, ERK, and JNK. Blood, 105:1598–1605. 2005.
328.
PekkariK, GurunathR, ArnerES, HolmgrenA. Truncated thioredoxin is a mitogenic cytokine for resting human peripheral blood mononuclear cells and is present in human plasma. J Biol Chem, 275:37474–37480. 2000.
PennisiG, CorneliusC, CavallaroMM, SalinaroAT, CambriaMT, PennisiM, BellaR, MiloneP, VentimigliaB, MiglioreMR, Di RenzoL, De LorenzoA, CalabreseV. Redox regulation of cellular stress response in multiple sclerosis. Biochem Pharmacol, 82:1490–1499. 2011.
331.
Perez-MatoI, CastroC, RuizFA, CorralesFJ, MatoJM. Methionine adenosyltransferase S-nitrosylation is regulated by the basic and acidic amino acids surrounding the target thiol. J Biol Chem, 274:17075–17079. 1999.
332.
PerezVI, CortezLA, LewCM, RodriguezM, WebbCR, Van RemmenH, ChaudhuriA, QiW, LeeS, BokovA, FokW, JonesD, RichardsonA, YodoiJ, ZhangY, TominagaK, HubbardGB, IkenoY. Thioredoxin 1 overexpression extends mainly the earlier part of life span in mice. J Gerontol A Biol Sci Med Sci, 66:1286–1299. 2011.
333.
PerezVI, LewCM, CortezLA, WebbCR, RodriguezM, LiuY, QiW, LiY, ChaudhuriA, Van RemmenH, RichardsonA, IkenoY. Thioredoxin 2 haploinsufficiency in mice results in impaired mitochondrial function and increased oxidative stress. Free Radic Biol Med, 44:882–892. 2008.
334.
PerezVI, Van RemmenH, BokovA, EpsteinCJ, VijgJ, RichardsonA. The overexpression of major antioxidant enzymes does not extend the lifespan of mice. Aging Cell, 8:73–75. 2009.
335.
PerroneL, DeviTS, HosoyaK, TerasakiT, SinghLP. Thioredoxin interacting protein (TXNIP) induces inflammation through chromatin modification in retinal capillary endothelial cells under diabetic conditions. J Cell Physiol, 221:262–272. 2009.
336.
PerroneL, DeviTS, HosoyaKI, TerasakiT, SinghLP. Inhibition of TXNIP expression in vivo blocks early pathologies of diabetic retinopathy. Cell Death Dis, 1:e65. 2010.
337.
PlassmanBL, LangaKM, FisherGG, HeeringaSG, WeirDR, OfstedalMB, BurkeJR, HurdMD, PotterGG, RodgersWL, SteffensDC, WillisRJ, WallaceRB. Prevalence of dementia in the United States: the aging, demographics, and memory study. Neuroepidemiology, 29:125–132. 2007.
338.
PowisG, KirkpatrickDL. Thioredoxin signaling as a target for cancer therapy. Curr Opin Pharmacol, 7:392–397. 2007.
339.
PowisG, MontfortWR. Properties and biological activities of thioredoxins. Annu Rev Biophys Biomol Struct, 30:421–455. 2001.
340.
PowisG, MustacichD, CoonA. The role of the redox protein thioredoxin in cell growth and cancer. Free Radic Biol Med, 29:312–322. 2000.
341.
PriceSA, GardinerNJ, Duran-JimenezB, ZeefLA, ObrosovaIG, TomlinsonDR. Thioredoxin interacting protein is increased in sensory neurons in experimental diabetes. Brain Res, 1116:206–214. 2006.
342.
ProfumoE, ButtariB, RiganoR. Oxidative stress in cardiovascular inflammation: its involvement in autoimmune responses. Int J Inflam, 2011:295705. 2011.
343.
PynnM, SchaferK, KonstantinidesS, HalleM. Exercise training reduces neointimal growth and stabilizes vascular lesions developing after injury in apolipoprotein e-deficient mice. Circulation, 109:386–392. 2004.
344.
RaffelJ, BhattacharyyaAK, GallegosA, CuiH, EinspahrJG, AlbertsDS, PowisG. Increased expression of thioredoxin-1 in human colorectal cancer is associated with decreased patient survival. J Lab Clin Med, 142:46–51. 2003.
345.
RajamakiK, LappalainenJ, OorniK, ValimakiE, MatikainenS, KovanenPT, EklundKK. Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: a novel link between cholesterol metabolism and inflammation. PLoS One, 5:e11765. 2010.
346.
RamanathanRK, AbbruzzeseJ, DragovichT, KirkpatrickL, GuillenJM, BakerAF, PestanoLA, GreenS, Von HoffDD. A randomized phase II study of PX-12, an inhibitor of thioredoxin in patients with advanced cancer of the pancreas following progression after a gemcitabine-containing combination. Cancer Chemother Pharmacol, 67:503–509. 2011.
347.
RamanathanRK, StephensonJJ, WeissGJ, PestanoLA, LoweA, HiscoxA, LeosRA, MartinJC, KirkpatrickL, RichardsDA. A phase I trial of PX-12, a small-molecule inhibitor of thioredoxin-1, administered as a 72-hour infusion every 21 days in patients with advanced cancers refractory to standard therapy. Invest New Drugs, 30:1591–1596. 2012.
348.
RancourtRC, TaiS, KingM, HeltsheSL, PenvariC, AccursoFJ, WhiteCW. Thioredoxin liquefies and decreases the viscoelasticity of cystic fibrosis sputum. Am J Physiol Lung Cell Mol Physiol, 286:L931–L938. 2004.
349.
RaoAK, ZieglerYS, McLeodIX, YatesJR, NardulliAM. Thioredoxin and thioredoxin reductase influence estrogen receptor alpha-mediated gene expression in human breast cancer cells. J Mol Endocrinol, 43:251–261. 2009.
350.
RaoCV. Regulation of COX and LOX by curcumin. Adv Exp Med Biol, 595:213–226. 2007.
351.
RaynerM, PetersenS. European cardiovascular disease statistics. British Heart Foundation. 2008. http://www.herzstifung.ch/uploads/media/European_cardiovascular_disease_statistics_2008.pdf.
352.
ReddyKS. Cardiovascular diseases in the developing countries: dimensions, determinants, dynamics and directions for public health action. Public Health Nutr, 5:231–237. 2002.
353.
RigobelloMP, ScutariG, FoldaA, BindoliA. Mitochondrial thioredoxin reductase inhibition by gold(I) compounds and concurrent stimulation of permeability transition and release of cytochrome c. Biochem Pharmacol, 67:689–696. 2004.
354.
RobertsonRP, HarmonJ, TranPO, PoitoutV. Beta-cell glucose toxicity, lipotoxicity, and chronic oxidative stress in type 2 diabetes. Diabetes, 53,Suppl 1:S119–S124. 2004.
355.
RocksN, BekaertS, CoiaI, PaulissenG, GuedersM, EvrardB, Van HeugenJC, ChiapP, FoidartJM, NoelA, CataldoD. Curcumin-cyclodextrin complexes potentiate gemcitabine effects in an orthotopic mouse model of lung cancer. Br J Cancer, 107:1083–1092. 2012.
356.
RogerVL, GoAS, Lloyd-JonesDM, AdamsRJ, BerryJD, BrownTM, CarnethonMR, DaiS, de SimoneG, FordES, FoxCS, FullertonHJ, GillespieC, GreenlundKJ, HailpernSM, HeitJA, HoPM, HowardVJ, KisselaBM, KittnerSJ, LacklandDT, LichtmanJH, LisabethLD, MakucDM, MarcusGM, MarelliA, MatcharDB, McDermottMM, MeigsJB, MoyCS, MozaffarianD, MussolinoME, NicholG, PaynterNP, RosamondWD, SorliePD, StaffordRS, TuranTN, TurnerMB, WongND, Wylie-RosettJ. Heart disease and stroke statistics—2011 update: a report from the American Heart Association. Circulation, 123:e18–e209. 2011.
357.
RohrbachS, GruenlerS, TeschnerM, HoltzJ. The thioredoxin system in aging muscle: key role of mitochondrial thioredoxin reductase in the protective effects of caloric restriction?Am J Physiol Regul Integr Comp Physiol, 291:R927–R935. 2006.
358.
RosenP, NawrothPP, KingG, MollerW, TritschlerHJ, PackerL. The role of oxidative stress in the onset and progression of diabetes and its complications: a summary of a Congress Series sponsored by UNESCO-MCBN, the American Diabetes Association and the German Diabetes Society. Diabetes Metab Res Rev, 17:189–212. 2001.
359.
RubartelliA, BajettoA, AllavenaG, WollmanE, SitiaR. Secretion of thioredoxin by normal and neoplastic cells through a leaderless secretory pathway. J Biol Chem, 267:24161–24164. 1992.
360.
RybnikovaE, DamdimopoulosAE, GustafssonJA, SpyrouG, Pelto-HuikkoM. Expression of novel antioxidant thioredoxin-2 in the rat brain. Eur J Neurosci, 12:1669–1678. 2000.
361.
SagherD, BrunellD, BrotN, ValleeBL, WeissbachH. Selenocompounds can serve as oxidoreductants with the methionine sulfoxide reductase enzymes. J Biol Chem, 281:31184–31187. 2006.
362.
SaitohM, NishitohH, FujiiM, TakedaK, TobiumeK, SawadaY, KawabataM, MiyazonoK, IchijoH. Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. EMBO J, 17:2596–2606. 1998.
363.
SalmonAB, PerezVI, BokovA, JerniganA, KimG, ZhaoH, LevineRL, RichardsonA. Lack of methionine sulfoxide reductase A in mice increases sensitivity to oxidative stress but does not diminish life span. FASEB J, 23:3601–3608. 2009.
364.
SamuelSM, ThirunavukkarasuM, PenumathsaSV, KoneruS, ZhanL, MaulikG, SudhakaranPR, MaulikN. Thioredoxin-1 gene therapy enhances angiogenic signaling and reduces ventricular remodeling in infarcted myocardium of diabetic rats. Circulation, 121:1244–1255. 2010.
365.
SandalovaT, ZhongL, LindqvistY, HolmgrenA, SchneiderG. Three-dimensional structure of a mammalian thioredoxin reductase: implications for mechanism and evolution of a selenocysteine-dependent enzyme. Proc Natl Acad Sci U S A, 98:9533–9538. 2001.
366.
SarteletH, RougemontAL, FabreM, CastaingM, DuvalM, FetniR, MichielsS, BeaunoyerM, VassalG. Activation of the phosphatidylinositol 3′-kinase/AKT pathway in neuroblastoma and its regulation by thioredoxin 1. Hum Pathol, 42:1727–1739. 2011.
367.
SatoN, IwataS, NakamuraK, HoriT, MoriK, YodoiJ. Thiol-mediated redox regulation of apoptosis. Possible roles of cellular thiols other than glutathione in T cell apoptosis. J Immunol, 154:3194–3203. 1995.
368.
SaxenaG, ChenJ, ShalevA. Intracellular shuttling and mitochondrial function of thioredoxin-interacting protein. J Biol Chem, 285:3997–4005. 2010.
369.
ScaliaR, GooszenME, JonesSP, HoffmeyerM, RimmerDM3rd, TrochaSD, HuangPL, SmithMB, LeferAM, LeferDJ. Simvastatin exerts both anti-inflammatory and cardioprotective effects in apolipoprotein E-deficient mice. Circulation, 103:2598–2603. 2001.
370.
SchenkH, KleinM, ErdbruggerW, DrogeW, Schulze-OsthoffK. Distinct effects of thioredoxin and antioxidants on the activation of transcription factors NF-kappa B and AP-1. Proc Natl Acad Sci U S A, 91:1672–1676. 1994.
371.
SchroderK, ZhouR, TschoppJ. The NLRP3 inflammasome: a sensor for metabolic danger?Science, 327:296–300. 2010.
372.
SchroederP, PoppR, WiegandB, AltschmiedJ, HaendelerJ. Nuclear redox-signaling is essential for apoptosis inhibition in endothelial cells—important role for nuclear thioredoxin-1. Arterioscler Thromb Vasc Biol, 27:2325–2331. 2007.
373.
SchulzePC, De KeulenaerGW, YoshiokaJ, KassikKA, LeeRT. Vitamin D3-upregulated protein-1 (VDUP-1) regulates redox-dependent vascular smooth muscle cell proliferation through interaction with thioredoxin. Circ Res, 91:689–695. 2002.
374.
SchulzePC, YoshiokaJ, TakahashiT, HeZ, KingGL, LeeRT. Hyperglycemia promotes oxidative stress through inhibition of thioredoxin function by thioredoxin-interacting protein. J Biol Chem, 279:30369–30374. 2004.
375.
ScrivoR, VasileM, BartosiewiczI, ValesiniG. Inflammation as “common soil” of the multifactorial diseases. Autoimmun Rev, 10:369–374. 2011.
376.
SenguptaR, HolmgrenA. Thioredoxin and thioredoxin reductase in relation to reversible S-nitrosylation. Antioxid Redox Signal, 18:259–269. 2013.
377.
SenguptaR, RyterSW, ZuckerbraunBS, TzengE, BilliarTR, StoyanovskyDA. Thioredoxin catalyzes the denitrosation of low-molecular mass and protein S-nitrosothiols. Biochemistry, 46:8472–8483. 2007.
378.
SeoAY, JosephAM, DuttaD, HwangJC, ArisJP, LeeuwenburghC. New insights into the role of mitochondria in aging: mitochondrial dynamics and more. J Cell Sci, 123:2533–2542. 2010.
379.
SeyfriedJ, WullnerU. Inhibition of thioredoxin reductase induces apoptosis in neuronal cell lines: role of glutathione and the MKK4/JNK pathway. Biochem Biophys Res Commun, 359:759–764. 2007.
380.
ShephardRJ, BaladyGJ. Exercise as cardiovascular therapy. Circulation, 99:963–972. 1999.
381.
Shern-BrewerR, SantanamN, WetzsteinC, White-WelkleyJ, ParthasarathyS. Exercise and cardiovascular disease: a new perspective. Arterioscler Thromb Vasc Biol, 18:1181–1187. 1998.
ShiY, RenY, ZhaoL, DuC, WangY, ZhangY, LiY, ZhaoS, DuanH. Knockdown of thioredoxin interacting protein attenuates high glucose-induced apoptosis and activation of ASK1 in mouse mesangial cells. FEBS Lett, 585:1789–1795. 2011.
385.
ShibataN, GlassCK. Regulation of macrophage function in inflammation and atherosclerosis. J Lipid Res, 50,Suppl:S277–S281. 2009.
386.
ShibukiH, KataiN, KuroiwaS, KurokawaT, YodoiJ, YoshimuraN. Protective effect of adult T-cell leukemia-derived factor on retinal ischemia-reperfusion injury in the rat. Invest Ophthalmol Vis Sci, 39:1470–1477. 1998.
387.
ShiojiK, KishimotoC, NakamuraH, MasutaniH, YuanZ, OkaS, YodoiJ. Overexpression of thioredoxin-1 in transgenic mice attenuates adriamycin-induced cardiotoxicity. Circulation, 106:1403–1409. 2002.
388.
SilbersteinDS, AliMH, BakerSL, DavidJR. Human eosinophil cytotoxicity-enhancing factor. purification, physical characteristics, and partial amino acid sequence of an active polypeptide. J Immunol, 143:979–983. 1989.
SkogastiernaC, JohanssonM, PariniP, ErikssonM, ErikssonLC, EkstromL, Bjorkhem-BergmanL. Statins inhibit expression of Thioredoxin reductase 1 in rat and human liver and reduce tumour development. Biochem Biophys Res Commun, 417:1046–1051. 2012.
391.
SmartDK, OrtizKL, MattsonD, BradburyCM, BishtKS, SieckLK, BrechbielMW, GiusD. Thioredoxin reductase as a potential molecular target for anticancer agents that induce oxidative stress. Cancer Res, 64:6716–6724. 2004.
392.
SoiniY, KahlosK, NapankangasU, Kaarteenaho-WiikR, SailyM, KoistinenP, PaaakkoP, HolmgrenA, KinnulaVL. Widespread expression of thioredoxin and thioredoxin reductase in non-small cell lung carcinoma. Clin Cancer Res, 7:1750–1757. 2001.
393.
SommerP, SweeneyG. Functional and mechanistic integration of infection and the metabolic syndrome. Korean Diabetes J, 34:71–76. 2010.
SprengerRR, FontijnRD, van MarleJ, PannekoekH, HorrevoetsAJ. Spatial segregation of transport and signalling functions between human endothelial caveolae and lipid raft proteomes. Biochem J, 400:401–410. 2006.
399.
SpyrouG, EnmarkE, Miranda-VizueteA, GustafssonJ. Cloning and expression of a novel mammalian thioredoxin. J Biol Chem, 272:2936–2941. 1997.
400.
StoltzmanCA, KaadigeMR, PetersonCW, AyerDE. MondoA senses non-glucose sugars: regulation of TXNIP and the hexose transport curb. J Biol Chem, 286:38027–38034. 2011.
401.
SumbayevVV. S-nitrosylation of thioredoxin mediates activation of apoptosis signal-regulating kinase 1. Arch Biochem Biophys, 415:133–136. 2003.
402.
SumidaS, NakamuraH, YodoiJ. Thioredoxin induction of peripheral blood mononuclear cells in mice in response to a single bout of swimming exercise. Gen Physiol Biophys, 23:241–249. 2004.
403.
SunQA, WuY, ZappacostaF, JeangKT, LeeBJ, HatfieldDL, GladyshevVN. Redox regulation of cell signaling by selenocysteine in mammalian thioredoxin reductases. J Biol Chem, 274:24522–24530. 1999.
404.
TakagiY, GonY, TodakaT, NozakiK, NishiyamaA, SonoH, HashimotoN, KikuchiH, YodoiJ. Expression of thioredoxin is enhanced in atherosclerotic plaques and during neointima formation in rat arteries. Lab Invest, 78:957–966. 1998.
405.
TakagiY, MitsuiA, NishiyamaA, NozakiK, SonoH, GonY, HashimotoN, YodoiJ. Overexpression of thioredoxin in transgenic mice attenuates focal ischemic brain damage. Proc Natl Acad Sci U S A, 96:4131–4136. 1999.
406.
TakahashiY, NagataT, IshiiY, IkarashiM, IshikawaK, AsaiS. Up-regulation of vitamin D3 up-regulated protein 1 gene in response to 5-fluorouracil in colon carcinoma SW620. Oncol Rep, 9:75–79. 2002.
407.
TaniguchiY, Taniguchi-UedaY, MoriK, YodoiJ. A novel promoter sequence is involved in the oxidative stress-induced expression of the adult T-cell leukemia-derived factor (ADF)/human thioredoxin (Trx) gene. Nucleic Acids Res, 24:2746–2752. 1996.
408.
TaoL, GaoE, BryanNS, QuY, LiuHR, HuA, ChristopherTA, LopezBL, YodoiJ, KochWJ, FeelischM, MaXL. Cardioprotective effects of thioredoxin in myocardial ischemia and reperfusion: role of S-nitrosation [corrected]Proc Natl Acad Sci U S A, 101:11471–11476. 2004.
TheobaldAJ, CaballeroI, ComaI, ColmenarejoG, CidC, GamoFJ, HibbsMJ, BassAL, ThomasDA. Discovery and biochemical characterization of plasmodium thioredoxin reductase inhibitors from an antimalarial set. Biochemistry, 51:4764–4771. 2012.
414.
TienrungrojW, PrattSE, GrippoJF, HolmgrenA, PrattWB. The heat-stable cytosolic factor that promotes glucocorticoid receptor binding to DNA is neither thioredoxin nor ribonuclease. J Steroid Biochem, 28:449–457. 1987.
415.
TiittoL, Kaarteenaho-WiikR, SormunenR, HolmgrenA, PaakkoP, SoiniY, KinnulaVL. Expression of the thioredoxin system in interstitial lung disease. J Pathol, 201:363–370. 2003.
416.
TonissenKF. Targeting the human thioredoxin system by diverse strategies to treat cancer and other pathologies. Recent Pat DNA Gene Seq, 1:164–175. 2007.
417.
TonissenKF, Di TrapaniG. Thioredoxin system inhibitors as mediators of apoptosis for cancer therapy. Mol Nutr Food Res, 53:87–103. 2009.
418.
TonissenKF, WellsJR. Isolation and characterization of human thioredoxin-encoding genes. Gene, 102:221–228. 1991.
TrachoothamD, AlexandreJ, HuangP. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?Nat Rev Drug Discov, 8:579–591. 2009.
421.
TsutsuiT, KoideH, FukahoriH, IsodaK, HigashiyamaS, MaedaI, TashiroF, YamatoE, MiyazakiJ, YodoiJ, KawaseM, YagiK. Adenoviral transfection of hepatocytes with the thioredoxin gene confers protection against apoptosis and necrosis. Biochem Biophys Res Commun, 307:765–770. 2003.
422.
TuranovAA, KehrS, MarinoSM, YooMH, CarlsonBA, HatfieldDL, GladyshevVN. Mammalian thioredoxin reductase 1: roles in redox homoeostasis and characterization of cellular targets. Biochem J, 430:285–293. 2010.
423.
TurocziT, ChangVW, EngelmanRM, MaulikN, HoYS, DasDK. Thioredoxin redox signaling in the ischemic heart: an insight with transgenic mice overexpressing Trx1. J Mol Cell Cardiol, 35:695–704. 2003.
424.
TurturroF, FridayE, WelbourneT. Hyperglycemia regulates thioredoxin-ROS activity through induction of thioredoxin-interacting protein (TXNIP) in metastatic breast cancer-derived cells MDA-MB-231. BMC Cancer, 7:96. 2007.
425.
UedaS, NakamuraH, MasutaniH, SasadaT, YoneharaS, TakabayashiA, YamaokaY, YodoiJ. Redox regulation of caspase-3(-like) protease activity: regulatory roles of thioredoxin and cytochrome c. J Immunol, 161:6689–6695. 1998.
426.
UedaS, NakamuraT, YamadaA, TerataniA, MatsuiN, FurukawaS, HoshinoY, NaritaM, YodoiJ, NakamuraH. Recombinant human thioredoxin suppresses lipopolysaccharide-induced bronchoalveolar neutrophil infiltration in rat. Life Sci, 79:1170–1177. 2006.
UmekawaT, SugiyamaT, KihiraT, MurabayashiN, ZhangL, NagaoK, KamimotoY, MaN, YodoiJ, SagawaN. Overexpression of thioredoxin-1 reduces oxidative stress in the placenta of transgenic mice and promotes fetal growth via glucose metabolism. Endocrinology, 149:3980–3988. 2008.
429.
UngerstedtJS, SowaY, XuWS, ShaoY, DokmanovicM, PerezG, NgoL, HolmgrenA, JiangX, MarksPA. Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc Natl Acad Sci U S A, 102:673–678. 2005.
430.
UngvariZ, KaleyG, de CaboR, SonntagWE, CsiszarA. Mechanisms of vascular aging: new perspectives. J Gerontol A Biol Sci Med Sci, 65:1028–1041. 2010.
431.
UrigS, BeckerK. On the potential of thioredoxin reductase inhibitors for cancer therapy. Semin Cancer Biol, 16:452–465. 2006.
432.
ValkoM, LeibfritzD, MoncolJ, CroninMT, MazurM, TelserJ. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol, 39:44–84. 2007.
433.
Vande WalleL, LamkanfiM. Inflammasomes: caspase-1-activating platforms with critical roles in host defense. Front Microbiol, 2:3. 2011.
434.
VassalleC, MercuriA, MaffeiS. Oxidative status and cardiovascular risk in women: Keeping pink at heart. World J Cardiol, 1:26–30. 2009.
435.
VeldmanCM, CantornaMT, DeLucaHF. Expression of 1,25-dihydroxyvitamin D(3) receptor in the immune system. Arch Biochem Biophys, 374:334–338. 2000.
436.
VenkateshappaC, HarishG, MahadevanA, Srinivas BharathMM, ShankarSK. Elevated oxidative stress and decreased antioxidant function in the human hippocampus and frontal cortex with increasing age: implications for neurodegeneration in Alzheimer's disease. Neurochem Res, 37:1601–1614. 2012.
WaakJ, WeberSS, GornerK, SchallC, IchijoH, StehleT, KahlePJ. Oxidizable residues mediating protein stability and cytoprotective interaction of DJ-1 with apoptosis signal-regulating kinase 1. J Biol Chem, 284:14245–14257. 2009.
439.
WakasugiN, TagayaY, WakasugiH, MitsuiA, MaedaM, YodoiJ, TurszT. Adult T-cell leukemia-derived factor/thioredoxin, produced by both human T-lymphotropic virus type I- and Epstein-Barr virus-transformed lymphocytes, acts as an autocrine growth factor and synergizes with interleukin 1 and interleukin 2. Proc Natl Acad Sci U S A, 87:8282–8286. 1990.
WangX, ZhangJ, XuT. Cyclophosphamide as a potent inhibitor of tumor thioredoxin reductase in vivo. Toxicol Appl Pharmacol, 218:88–95. 2007.
442.
WangX, ZhangJ, XuT. Thioredoxin reductase inactivation as a pivotal mechanism of ifosfamide in cancer therapy. Eur J Pharmacol, 579:66–73. 2008.
443.
WangY, LiuT, WuC, LiH. A strategy for direct identification of protein S-nitrosylation sites by quadrupole time-of-flight mass spectrometry. J Am Soc Mass Spectrom, 19:1353–1360. 2008.
444.
WangZ, RongYP, MaloneMH, DavisMC, ZhongF, DistelhorstCW. Thioredoxin-interacting protein (txnip) is a glucocorticoid-regulated primary response gene involved in mediating glucocorticoid-induced apoptosis. Oncogene, 25:1903–1913. 2006.
445.
WatanabeR, NakamuraH, MasutaniH, YodoiJ. Anti-oxidative, anti-cancer and anti-inflammatory actions by thioredoxin 1 and thioredoxin-binding protein-2. Pharmacol Ther, 127:261–270. 2010.
446.
WeiYH, LeeHC. Oxidative stress, mitochondrial DNA mutation, and impairment of antioxidant enzymes in aging. Exp Biol Med (Maywood), 227:671–682. 2002.
447.
WeichselA, BraileyJL, MontfortWR. Buried S-nitrosocysteine revealed in crystal structures of human thioredoxin. Biochemistry, 46:1219–1227. 2007.
448.
WellsG, BerryJM, BradshawTD, BurgerAM, SeatonA, WangB, WestwellAD, StevensMF. 4-Substituted 4-hydroxycyclohexa-2,5-dien-1-ones with selective activities against colon and renal cancer cell lines. J Med Chem, 46:532–541. 2003.
449.
WelshSJ, WilliamsRR, BirminghamA, NewmanDJ, KirkpatrickDL, PowisG. The thioredoxin redox inhibitors 1-methylpropyl 2-imidazolyl disulfide and pleurotin inhibit hypoxia-induced factor 1alpha and vascular endothelial growth factor formation. Mol Cancer Ther, 2:235–243. 2003.
450.
WetzsteinCJ, Shern-BrewerRA, SantanamN, GreenNR, White-WelkleyJE, ParthasarathyS. Does acute exercise affect the susceptibility of low density lipoprotein to oxidation?Free Radic Biol Med, 24:679–682. 1998.
451.
WidderJD, FraccarolloD, GaluppoP, HansenJM, JonesDP, ErtlG, BauersachsJ. Attenuation of angiotensin II-induced vascular dysfunction and hypertension by overexpression of Thioredoxin 2. Hypertension, 54:338–344. 2009.
452.
WitteAB, AnestalK, JerremalmE, EhrssonH, ArnerES. Inhibition of thioredoxin reductase but not of glutathione reductase by the major classes of alkylating and platinum-containing anticancer compounds. Free Radic Biol Med, 39:696–703. 2005.
453.
WorldC, SpindelON, BerkBC. Thioredoxin-interacting protein mediates TRX1 translocation to the plasma membrane in response to tumor necrosis factor-alpha: a key mechanism for vascular endothelial growth factor receptor-2 transactivation by reactive oxygen species. Arterioscler Thromb Vasc Biol, 31:1890–1897. 2011.
XanthoudakisS, CurranT. Identification and characterization of Ref-1, a nuclear protein that facilitates AP-1 DNA-binding activity. EMBO J, 11:653–665. 1992.
456.
XuJ, LiT, WuH, XuT. Role of thioredoxin in lung disease. Pulm Pharmacol Ther, 25:154–162. 2012.
YamadaY, NakamuraH, AdachiT, SannoheS, OyamadaH, KayabaH, YodoiJ, ChiharaJ. Elevated serum levels of thioredoxin in patients with acute exacerbation of asthma. Immunol Lett, 86:199–205. 2003.
459.
YamamotoM, YamatoE, ToyodaS, TashiroF, IkegamiH, YodoiJ, MiyazakiJ. Transgenic expression of antioxidant protein thioredoxin in pancreatic beta cells prevents progression of type 2 diabetes mellitus. Antioxid Redox Signal, 10:43–49. 2008.
460.
YamamotoM, YangG, HongC, LiuJ, HolleE, YuX, WagnerT, VatnerSF, SadoshimaJ. Inhibition of endogenous thioredoxin in the heart increases oxidative stress and cardiac hypertrophy. J Clin Invest, 112:1395–1406. 2003.
461.
YamawakiH, HaendelerJ, BerkBC. Thioredoxin: a key regulator of cardiovascular homeostasis. Circ Res, 93:1029–1033. 2003.
462.
YangR, WeberDJ, CarrierF. Post-transcriptional regulation of thioredoxin by the stress inducible heterogenous ribonucleoprotein A18. Nucleic Acids Res, 34:1224–1236. 2006.
463.
YinT, HouR, LiuS, LauWB, WangH, TaoL. Nitrative inactivation of thioredoxin-1 increases vulnerability of diabetic hearts to ischemia/reperfusion injury. J Mol Cell Cardiol, 49:354–361. 2010.
464.
YodoiJ, TurszT. ADF, a growth-promoting factor derived from adult T cell leukemia and homologous to thioredoxin: involvement in lymphocyte immortalization by HTLV-I and EBV. Adv Cancer Res, 57:381–411. 1991.
YooMH, XuXM, CarlsonBA, PattersonAD, GladyshevVN, HatfieldDL. Targeting thioredoxin reductase 1 reduction in cancer cells inhibits self-sufficient growth and DNA replication. PLoS One, 2:e1112. 2007.
467.
YoshidaS, KatohT, TetsukaT, UnoK, MatsuiN, OkamotoT. Involvement of thioredoxin in rheumatoid arthritis: its costimulatory roles in the TNF-alpha-induced production of IL-6 and IL-8 from cultured synovial fibroblasts. J Immunol, 163:351–358. 1999.
468.
YoshidaT, OkaS, MasutaniH, NakamuraH, YodoiJ. The role of thioredoxin in the aging process: involvement of oxidative stress. Antioxid Redox Signal, 5:563–570. 2003.
469.
YoshiharaE, FujimotoS, InagakiN, OkawaK, MasakiS, YodoiJ, MasutaniH. Disruption of TBP-2 ameliorates insulin sensitivity and secretion without affecting obesity. Nat Commun, 1:127. 2010.
470.
YoshiokaJ, ChutkowWA, LeeS, KimJB, YanJ, TianR, LindseyML, FeenerEP, SeidmanCE, SeidmanJG, LeeRT. Deletion of thioredoxin-interacting protein in mice impairs mitochondrial function but protects the myocardium from ischemia-reperfusion injury. J Clin Invest, 122:267–279. 2012.
471.
YoshiokaJ, SchulzePC, CupesiM, SylvanJD, MacGillivrayC, GannonJ, HuangH, LeeRT. Thioredoxin-interacting protein controls cardiac hypertrophy through regulation of thioredoxin activity. Circulation, 109:2581–2586. 2004.
472.
YoudimMB, BakhleYS. Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness. Br J Pharmacol, 147,Suppl 1:S287–S296. 2006.
473.
Zahedi AvvalF, HolmgrenA. Molecular mechanisms of thioredoxin and glutaredoxin as hydrogen donors for Mammalian s phase ribonucleotide reductase. J Biol Chem, 284:8233–8240. 2009.
474.
ZhangH, LuoY, ZhangW, HeY, DaiS, ZhangR, HuangY, BernatchezP, GiordanoFJ, ShadelG, SessaWC, MinW. Endothelial-specific expression of mitochondrial thioredoxin improves endothelial cell function and reduces atherosclerotic lesions. Am J Pathol, 170:1108–1120. 2007.
475.
ZhangJ, ChenF, NakamuraT, FujinagaT, AoyamaA, HamakawaH, SakaiH, HoshinoY, YodoiJ, WadaH, BandoT, NakamuraH. Protective effect of thioredoxin perfusion but not inhalation in warm ischemic-reperfused rat lungs. Redox Rep, 14:75–81. 2009.
476.
ZhangJ, LiYD, PatelJM, BlockER. Thioredoxin overexpression prevents NO-induced reduction of NO synthase activity in lung endothelial cells. Am J Physiol, 275:L288–L293. 1998.
477.
ZhangR, Al-LamkiR, BaiL, StrebJW, MianoJM, BradleyJ, MinW. Thioredoxin-2 inhibits mitochondria-located ASK1-mediated apoptosis in a JNK-independent manner. Circ Res, 94:1483–1491. 2004.
478.
ZhouR, TardivelA, ThorensB, ChoiI, TschoppJ. Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat Immunol, 11:136–140. 2010.
479.
ZiekerD, FehrenbachE, DietzschJ, FliegnerJ, WaidmannM, NieseltK, Gebicke-HaerterP, SpanagelR, SimonP, NiessAM, NorthoffH. cDNA microarray analysis reveals novel candidate genes expressed in human peripheral blood following exhaustive exercise. Physiol Genomics, 23:287–294. 2005.
